

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02575 A1

(51) International Patent Classification⁷: **C12N 15/31**,
15/62, 15/85, C07K 14/295, 16/12, A61K 31/711, 39/118,
39/40, G01N 33/53

(74) Agents: **MORROW, Joy, D.** et al.; Smart & Biggar,
900-55 Metcalfe Street, Station D, P.O. Box 2999, Ottawa,
Ontario K1P 5Y6 (CA).

(21) International Application Number: PCT/CA00/00778

(22) International Filing Date: 28 June 2000 (28.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/141,270 30 June 1999 (30.06.1999) US

(71) Applicant (for all designated States except US): **AVEN-
TIS PASTEUR LIMITED** [CA/CA]; Connaught Cam-
pus, Corporate Patent Dept., 1755 Steeles Avenue, West,
Toronto, Ontario M2R 3T4 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MURDIN, Andrew**,
D. [CA/CA]; 146 Rhodes Circle, Newmarket, Ontario
L3X 1V2 (CA). **OOMEN, Raymond, P.** [CA/CA]; 29
Kennedy St. W., Aurora, Ontario L4G 2L6 (CA). **WANG,**
Joe [CA/CA]; 48 29th Street, Etobicoke, Ontario M8W
3A8 (CA). **DUNN, Pamela** [GB/CA]; Apartment 703, 370
Kaneff Crescent, Mississauga, Ontario L5A 4B8 (CA).

(54) Title: **CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF**

(57) Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of *Chlamydia*, specifically *C. pneumoniae*, employing a vector containing a nucleotide sequence encoding an orfF polypeptide of a strain of *Chlamydia pneumoniae* and a promotor to effect expression of the orfF gene in the host. Modifications are possible within the scope of this invention.



WO 01/02575 A1

TITLE OF INVENTION

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of U.S.
Provisional Application No. 60/141,270, filed June 30, 1999.

FIELD OF INVENTION

The present invention relates to the *Chlamydia*
polypeptides designated orfF and corresponding DNA molecules,
10 which can be used to prevent and treat *Chlamydia* infection in
mammals, such as humans.

BACKGROUND OF THE INVENTION

Chlamydiae are prokaryotes. They exhibit morphologic
and structural similarities to gram-negative bacteria including
15 a trilaminar outer membrane, which contains lipopolysaccharide
and several membrane proteins that are structurally and
functionally analogous to proteins found in *E coli*. They are
obligate intra-cellular parasites with a unique biphasic life
cycle consisting of a metabolically inactive but infectious
20 extracellular stage and a replicating but non-infectious
intracellular stage. The replicative stage of the life-cycle
takes place within a membrane-bound inclusion which sequesters
the bacteria away from the cytoplasm of the infected host cell.

C. pneumoniae is a common human pathogen, originally
25 described as the TWAR strain of *Chlamydia psittaci* but
subsequently recognised to be a new species. *C. pneumoniae* is
antigenically, genetically and morphologically distinct from
other *Chlamydia* species (*C. trachomatis*, *C. pecorum* and *C.*
psittaci). It shows 10% or less DNA sequence homology with
30 either of *C. trachomatis* or *C. psittaci*.

C. pneumoniae is a common cause of community acquired
pneumonia, only less frequent than *Streptococcus pneumoniae* and

Mycoplasma pneumoniae (Grayston et al. (1995) Journal of Infectious Diseases 168:1231; Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477). It can also cause upper respiratory tract symptoms and disease, including bronchitis and sinusitis (Grayston et al. (1995) Journal of Infectious Diseases 168:1231; Grayston et al (1990) Journal of Infectious Diseases 161:618; Marrie (1993) Clinical Infectious Diseases. 18:501; Wang et al (1986) Chlamydial infections Cambridge University Press, Cambridge. p. 329. The great majority of the adult population (over 60%) has antibodies to *C. pneumoniae* (Wang et al (1986) Chlamydial infections. Cambridge University Press, Cambridge. p. 329), indicating past infection which was unrecognized or asymptomatic.

C. pneumoniae infection usually presents as an acute respiratory disease (i.e., cough, sore throat, hoarseness, and fever; abnormal chest sounds on auscultation). For most patients, the cough persists for 2 to 6 weeks, and recovery is slow. In approximately 10% of these cases, upper respiratory tract infection is followed by bronchitis or pneumonia. Furthermore, during a *C. pneumoniae* epidemic, subsequent co-infection with pneumococcus has been noted in about half of these pneumonia patients, particularly in the infirm and the elderly. As noted above, there is more and more evidence that *C. pneumoniae* infection is also linked to diseases other than respiratory infections.

The reservoir for the organism is presumably people. In contrast to *C. psittaci* infections, there is no known bird or animal reservoir. Transmission has not been clearly defined. It may result from direct contact with secretions, from fomites, or from airborne spread. There is a long incubation period, which may last for many months. Based on analysis of epidemics, *C. pneumoniae* appears to spread slowly through a population (case-to-case interval averaging 30 days)

because infected persons are inefficient transmitters of the organism. Susceptibility to *C. pneumoniae* is universal. Reinfections occur during adulthood, following the primary infection as a child. *C. pneumoniae* appears to be an endemic
5 disease throughout the world, noteworthy for superimposed intervals of increased incidence (epidemics) that persist for 2 to 3 years. *C. trachomatis* infection does not confer cross-immunity to *C. pneumoniae*. Infections are easily treated with oral antibiotics, tetracycline or erythromycin (2 g/d, for at
10 least 10 to 14 d). A recently developed drug, azithromycin, is highly effective as a single-dose therapy against Chlamydial infections.

In most instances, *C. pneumoniae* infection is often mild and without complications, and up to 90% of infections are
15 subacute or unrecognized. Among children in industrialized countries, infections have been thought to be rare up to the age of 5 y, although a recent study (E Normann et al, *Chlamydia pneumoniae* in children with acute respiratory tract infections, Acta Paediatrica, 1998, Vol 87, Iss 1, pp 23-27) has reported
20 that many children in this age group show PCR evidence of infection despite being seronegative, and estimates a prevalence of 17-19% in 2-4 y olds. In developing countries, the seroprevalence of *C. pneumoniae* antibodies among young children is elevated, and there are suspicions that *C.*
25 *pneumoniae* may be an important cause of acute lower respiratory tract disease and mortality for infants and children in tropical regions of the world.

From seroprevalence studies and studies of local epidemics, the initial *C. pneumoniae* infection usually happens
30 between the ages of 5 and 20 y. In the USA, for example, there are estimated to be 30,000 cases of childhood pneumonia each year caused by *C. pneumoniae*. Infections may cluster among groups of children or young adults (e.g., school pupils or military conscripts).

C. pneumoniae causes 10 to 25% of community-acquired lower respiratory tract infections (as reported from Sweden, Italy, Finland, and the USA). During an epidemic, *C. pneumonia* infection may account for 50 to 60% of the cases of pneumonia. During these periods, also, more episodes of mixed infections with *S. pneumoniae* have been reported.

Reinfection during adulthood is common; the clinical presentation tends to be milder. Based on population seroprevalence studies, there tends to be increased exposure with age, which is particularly evident among men. Some investigators have speculated that a persistent, asymptomatic *C. pneumoniae* infection state is common.

In adults of middle age or older, *C. pneumoniae* infection may progress to chronic bronchitis and sinusitis. A study in the USA revealed that the incidence of pneumonia caused by *C. pneumoniae* in persons younger than 60 years is 1 case per 1,000 persons per year; but in the elderly, the disease incidence rose three-fold. *C. pneumoniae* infection rarely leads to hospitalization, except in patients with an underlying illness.

Of considerable importance is the association of atherosclerosis and *C. pneumoniae* infection. There are several epidemiological studies showing a correlation of previous infections with *C. pneumoniae* and heart attacks, coronary artery and carotid artery disease (Saikku et al.(1988) Lancet;ii:983; Thom et al. (1992) JAMA 268:68; Linnanmaki et al. (1993), Circulation 87:1030; Saikku et al. (1992)Annals Internal Medicine 116:273; Melnick et al(1993) American Journal of Medicine 95:499). Moreover, the organisms has been detected in atheromas and fatty streaks of the coronary, carotid, peripheral arteries and aorta (Shor et al. (1992) South African. Medical Journal 82:158; Kuo et al. (1993) Journal of Infectious Diseases 167:841; Kuo et al. (1993) Arteriosclerosis and Thrombosis 13:1500; Campbell et al (1995) Journal of

Infectious Diseases 172:585; Chiu et al. Circulation, 1997 (In Press)). Viable *C. pneumoniae* has been recovered from the coronary and carotid artery (Ramirez et al (1996) Annals of Internal Medicine 125:979; Jackson et al. Abst. K121, p272, 5 36th ICAAC, 15-18 Sept. 1996, New Orleans). Furthermore, it has been shown that *C. pneumoniae* can induce changes of atherosclerosis in a rabbit model (Fong et al (1997) Journal of Clinical Microbiology 35:48). Taken together, these results indicate that it is highly probable that *C. pneumoniae* can 10 cause atherosclerosis in humans, though the epidemiological importance of Chlamydial atherosclerosis remains to be demonstrated.

A number of recent studies have also indicated an association between *C. pneumoniae* infection and asthma. 15 Infection has been linked to wheezing, asthmatic bronchitis, adult-onset asthma and acute exacerbations of asthma in adults, and small-scale studies have shown that prolonged antibiotic treatment was effective at greatly reducing the severity of the disease in some individuals (Hahn DL, et al. Evidence for 20 *Chlamydia pneumoniae* infection in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1998 Jan; 80(1): 45-49.; Hahn DL, et al. Association of *Chlamydia pneumoniae* IgA antibodies with recently symptomatic asthma. Epidemiol Infect. 1996 Dec; 117(3): 513-517; Bjornsson E, et al. Serology of *Chlamydia* in 25 relation to asthma and bronchial hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69.; Hahn DL. Treatment of *Chlamydia pneumoniae* infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351.; Allegra L, et al. Acute exacerbations of asthma in adults: role of *Chlamydia* 30 *pneumoniae* infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168.; Hahn DL, et al. Association of *Chlamydia pneumoniae* (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230).

In light of these results a protective vaccine against *C. pneumoniae* infection would be of considerable importance. There is not yet an effective vaccine for any human Chlamydial infection. It is conceivable that an effective vaccine can be developed using physically or chemically inactivated Chlamydiae. However, such a vaccine does not have a high margin of safety. In general, safer vaccines are made by genetically manipulating the organism by attenuation or by recombinant means. Accordingly, a major obstacle in creating an effective and safe vaccine against human Chlamydial infection has been the paucity of genetic information regarding *Chlamydia*, specifically *C. pneumoniae*.

Studies with *C. trachomatis* and *C. psittaci* indicate that safe and effective vaccine against *Chlamydia* is an attainable goal. For example, mice which have recovered from a lung infection with *C. trachomatis* are protected from infertility induced by a subsequent vaginal challenge (Pal et al. (1996) Infection and Immunity.64:5341). Similarly, sheep immunized with inactivated *C. psittaci* were protected from subsequent Chlamydial-induced abortions and stillbirths (Jones et al. (1995) Vaccine 13:715). Protection from Chlamydial infections has been associated with Th1 immune responses, particularly the induction of INF γ - producing CD4+T-cells (Igiertsemes et al. (1993) Immunology 5:317). The adoptive transfer of CD4+ cell lines or clones to nude or SCID mice conferred protection from challenge or cleared chronic disease (Igiertseme et al (1993) Regional Immunology 5:317; Magee et al (1993) Regional Immunology 5: 305), and *in vivo* depletion of CD4+ T cells exacerbated disease post-challenge (Landers et al (1991) Infection & Immunity 59:3774; Magee et al (1995) Infection & Immunity 63:516). However, the presence of sufficiently high titres of neutralising antibody at mucosal surfaces can also exert a protective effect (Cotter et al. (1995) Infection and Immunity 63:4704).

Antigenic variation within the species *C. pneumoniae* is not well documented due to insufficient genetic information, though variation is expected to exist based on *C. trachomatis*. Serovars of *C. trachomatis* are defined on the basis of antigenic variation in the major outer membrane protein (MOMP), but published *C. pneumoniae* MOMP gene sequences show no variation between several diverse isolates of the organism (Campbell et al (1990) Infection and Immunity 58:93; McCafferty et al (1995) Infection and Immunity 63:2387-9; Knudsen et al (1996) Third Meeting of the European Society for Chlamydia Research, Vienna). The gene encoding a 76 kDa antigen has been cloned from a single strain of *C. pneumoniae* and the sequence published (Perez Melgosa et al., Infect. Immun. 1994. 62:880). An operon encoding the 9 kDa and 60 kDa cyteine-rich outer membrane protein genes has been described (Watson et al., Nucleic Acids Res (1990) 18:5299; Watson et al., Microbiology (1995) 141:2489). Many antigens recognized by immune sera to *C. pneumoniae* are conserved across all *Chlamydiae*, but 98 kDa, 76 kDa and several other proteins may be *C. pneumoniae*-specific (Perez Melgosa et al., Infect. Immun. 1994. 62:880; Melgosa et al., FEMS Microbiol Lett (1993) 112 :199;; Campbell et al., J Clin Microbiol (1990) 28 :1261; Iijima et al., J Clin Microbiol (1994) 32:583). An assessment of the number and relative frequency of any *C. pneumoniae* serotypes, and the defining antigens, is not yet possible. The entire genome sequence of *C. pneumoniae* strain CWL-029 is now known (<http://chlamydia-www.berkeley.edu:4231/>) and as further sequences become available a better understanding of antigenic variation may be gained.

Many antigens recognised by immune sera to *C. pneumoniae* are conserved across all *Chlamydiae*, but 98kDa, 76 kDa and 54 kDa proteins appear to be *C. pneumoniae*-specific (Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477; Marrie (1993) Clinical Infectious Diseases.

18:501; Wiedmann-Al-Ahmad M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of *Chlamydia pneumoniae*. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704).

5 Immunoblotting of isolates with sera from patients does show variation of blotting patterns between isolates, indicating that serotypes *C. pneumoniae* may exist (Grayston et al. (1995) Journal of Infectious Diseases 168:1231; Ramirez et al (1996) Annals of Internal Medicine 125:979). However, the
10 results are potentially confounded by the infection status of the patients, since immunoblot profiles of a patient's sera change with time post-infection. An assessment of the number and relative frequency of any serotypes, and the defining antigens, is not yet possible.

15 Accordingly, a need exists for identifying and isolating polynucleotide sequences of *C. pneumoniae* for use in preventing and treating *Chlamydia* infection.

SUMMARY OF THE INVENTION

The present invention provides purified and isolated
20 polynucleotide molecules that encode the *Chlamydia* polypeptides designated orfF (SEQ ID No: 1) which can be used in methods to prevent, treat, and diagnose *Chlamydia* infection. In one form of the invention, the polynucleotide molecules are DNA that encode the polypeptide of SEQ ID No: 2.

25 Another form of the invention provides polypeptides corresponding to the isolated DNA molecules. The amino acid sequence of the corresponding encoded polypeptide is shown as SEQ ID No: 2.

Those skilled in the art will readily understand that
30 the invention, having provided the polynucleotide sequences encoding the *Chlamydia* orfF polypeptide, also provides polynucleotides encoding fragments derived from such a polypeptide. Moreover, the invention is understood to provide

mutants and derivatives of such polypeptides and fragments derived therefrom, which result from the addition, deletion, or substitution of non-essential amino acids as described herein. Those skilled in the art would also readily understand that the invention, having provided the polynucleotide sequences encoding *Chlamydia* polypeptides, further provides monospecific antibodies that specifically bind to such polypeptides.

The present invention has wide application and includes expression cassettes, vectors, and cells transformed or transfected with the polynucleotides of the invention. Accordingly, the present invention further provides (i) a method for producing a polypeptide of the invention in a recombinant host system and related expression cassettes, vectors, and transformed or transfected cells; (ii) a vaccine, or a live vaccine vector such as a pox virus, *Salmonella typhimurium*, or *Vibrio cholerae* vector, containing a polynucleotide of the invention, such vaccines and vaccine vectors being useful for, e.g., preventing and treating *Chlamydia* infection, in combination with a diluent or carrier, and related pharmaceutical compositions and associated therapeutic and/or prophylactic methods; (iii) a therapeutic and/or prophylactic use of an RNA or DNA molecule of the invention, either in a naked form or formulated with a delivery vehicle, a polypeptide or combination of polypeptides, or a monospecific antibody of the invention, and related pharmaceutical compositions; (iv) a method for diagnosing the presence of *Chlamydia* in a biological sample, which can involve the use of a DNA or RNA molecule, a monospecific antibody, or a polypeptide of the invention; and (v) a method for purifying a polypeptide of the invention by antibody-based affinity chromatography.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following description with reference to the drawings, in which:

5 Figure 1 shows the nucleotide sequence of the orfF gene (SEQ ID No: 1) and the deduced amino acid sequence of the orfF polypeptide from *Chlamydia pneumoniae* (SEQ ID No: 2).

 Figure 2 shows the restriction enzyme analysis of the *C. pneumoniae* orfF gene.

10 Figure 3 shows the construction and elements of plasmid pCAI236.

 Figure 4 illustrates protection against *C. pneumoniae* infection by pCAI236 following DNA immunization.

DETAILED DESCRIPTION OF INVENTION

15 An open reading frame (ORF) encoding the Chlamydial orfF polypeptide has been identified from the *C. pneumoniae* genome. The gene encoding this protein has been inserted into an expression plasmid and shown to confer immune protection against Chlamydial infection. Accordingly, this orfF
20 polypeptide and related polypeptides can be used to prevent and treat *Chlamydia* infection.

 According to a first aspect of the invention, isolated polynucleotides are provided which encode *Chlamydia* polypeptides, whose amino acid sequences are shown in SEQ ID
25 No: 2.

 The term "isolated polynucleotide" is defined as a polynucleotide removed from the environment in which it naturally occurs. For example, a naturally-occurring DNA molecule present in the genome of a living bacteria or as part
30 of a gene bank is not isolated, but the same molecule separated from the remaining part of the bacterial genome, as a result of, e.g., a cloning event (amplification), is isolated. Typically, an isolated DNA molecule is free from DNA regions (e.g., coding regions) with which it is immediately contiguous

at the 5' or 3' end, in the naturally occurring genome. Such isolated polynucleotides may be part of a vector or a composition and still be defined as isolated in that such a vector or composition is not part of the natural environment of such polynucleotide.

The polynucleotide of the invention is either RNA or DNA (cDNA, genomic DNA, or synthetic DNA), or modifications, variants, homologs or fragments thereof. The DNA is either double-stranded or single-stranded, and, if single-stranded, is either the coding strand or the non-coding (anti-sense) strand. Any one of the sequences that encode the polypeptides of the invention as shown in SEQ ID No: 1 is (a) a coding sequence, (b) a ribonucleotide sequence derived from transcription of (a), or (c) a coding sequence which uses the redundancy or degeneracy of the genetic code to encode the same polypeptides. By "polypeptide" or "protein" is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). Both terms are used interchangeably in the present application.

Consistent with the first aspect of the invention, amino acid sequences are provided which are homologous to SEQ ID No: 2. As used herein, "homologous amino acid sequence" is any polypeptide which is encoded, in whole or in part, by a nucleic acid sequence which hybridizes at 25-35°C below critical melting temperature (T_m), to any portion of the nucleic acid sequence of SEQ ID No: 1. A homologous amino acid sequence is one that differs from an amino acid sequence shown in SEQ ID No: 2 by one or more conservative amino acid substitutions. Such a sequence also encompass serotypic variants (defined below) as well as sequences containing deletions or insertions which retain inherent characteristics of the polypeptide such as immunogenicity. Preferably, such a sequence is at least 75%, more preferably 80%, and most preferably 90% identical to SEQ ID No: 2.

Homologous amino acid sequences include sequences that are identical or substantially identical to SEQ ID No: 2. By "amino acid sequence substantially identical" is meant a sequence that is at least 90%, preferably 95%, more preferably 5 97%, and most preferably 99% identical to an amino acid sequence of reference and that preferably differs from the sequence of reference by a majority of conservative amino acid substitutions.

Conservative amino acid substitutions are 10 substitutions among amino acids of the same class. These classes include, for example, amino acids having uncharged polar side chains, such as asparagine, glutamine, serine, threonine, and tyrosine; amino acids having basic side chains, such as lysine, arginine, and histidine; amino acids having 15 acidic side chains, such as aspartic acid and glutamic acid; and amino acids having nonpolar side chains, such as glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine.

Homology is measured using sequence analysis software 20 such as Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705. Amino acid sequences are aligned to maximize identity. Gaps may be artificially introduced into the sequence to attain proper 25 alignment. Once the optimal alignment has been set up, the degree of homology is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.

Homologous polynucleotide sequences are defined in a 30 similar way. Preferably, a homologous sequence is one that is at least 45%, more preferably 60%, and most preferably 85% identical to the coding sequence of SEQ ID No: 1.

Consistent with the first aspect of the invention, polypeptides having a sequence homologous to SEQ ID No: 2

include naturally-occurring allelic variants, as well as mutants or any other non-naturally occurring variants that retain the inherent characteristics of the polypeptide of SEQ ID No: 2.

5 As is known in the art, an allelic variant is an alternate form of a polypeptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does not alter the biological function of the polypeptide. By "biological function" is meant the function of
10 the polypeptide in the cells in which it naturally occurs, even if the function is not necessary for the growth or survival of the cells. For example, the biological function of a porin is to allow the entry into cells of compounds present in the extracellular medium. Biological function is distinct from
15 antigenic property. A polypeptide can have more than one biological function.

 Allelic variants are very common in nature. For example, a bacterial species such as *C. pneumoniae*, is usually represented by a variety of strains that differ from each other
20 by minor allelic variations. Indeed, a polypeptide that fulfills the same biological function in different strains can have an amino acid sequence (and polynucleotide sequence) that is not identical in each of the strains. Despite this variation, an immune response directed generally against many
25 allelic variants has been demonstrated. In studies of the *Chlamydial* MOMP antigen, cross-strain antibody binding plus neutralization of infectivity occurs despite amino acid sequence variation of MOMP from strain to strain, indicating that the MOMP, when used as an immunogen, is tolerant of amino
30 acid variations.

 Polynucleotides encoding homologous polypeptides or allelic variants are retrieved by polymerase chain reaction (PCR) amplification of genomic bacterial DNA extracted by conventional methods. This involves the use of synthetic

oligonucleotide primers matching upstream and downstream of the 5' and 3' ends of the encoding domain. Suitable primers are designed according to the nucleotide sequence information provided in SEQ ID No:1. The procedure is as follows: a primer
5 is selected which consists of 10 to 40, preferably 15 to 25 nucleotides. It is advantageous to select primers containing C and G nucleotides in a proportion sufficient to ensure efficient hybridization; *i.e.*, an amount of C and G nucleotides of at least 40%, preferably 50% of the total nucleotide
10 content. A standard PCR reaction contains typically 0.5 to 5 Units of Taq DNA polymerase per 100 μ L, 20 to 200 μ M deoxynucleotide each, preferably at equivalent concentrations, 0.5 to 2.5 mM magnesium over the total deoxynucleotide concentration, 10^5 to 10^6 target molecules, and about 20 pmol
15 of each primer. About 25 to 50 PCR cycles are performed, with an annealing temperature 15°C to 5°C below the true T_m of the primers. A more stringent annealing temperature improves discrimination against incorrectly annealed primers and reduces incorporation of incorrect nucleotides at the 3' end of primers.
20 A denaturation temperature of 95°C to 97°C is typical, although higher temperatures may be appropriate for dematuration of G+C-rich targets. The number of cycles performed depends on the starting concentration of target molecules, though typically more than 40 cycles is not recommended as non-specific
25 background products tend to accumulate.

An alternative method for retrieving polynucleotides encoding homologous polypeptides or allelic variants is by hybridization screening of a DNA or RNA library. Hybridization procedures are well-known in the art and are described in
30 Ausubel *et al.*, (Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994), Silhavy *et al.* (Silhavy *et al.* Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, 1984), and Davis *et al.* (Davis *et al.* A

Manual for Genetic Engineering: Advanced Bacterial Genetics, Cold Spring Harbor Laboratory Press, 1980)). Important parameters for optimizing hybridization conditions are reflected in a formula used to obtain the critical melting temperature above which two complementary DNA strands separate from each other (Casey & Davidson, Nucl. Acid Res. (1977) 4:1539). For polynucleotides of about 600 nucleotides or larger, this formula is as follows: $T_m = 81.5 + 0.41 \times (\% \text{ G+C}) + 16.6 \log (\text{cation ion concentration}) - 0.63 \times (\% \text{ formamide}) - 600/\text{base number}$. Under appropriate stringency conditions, hybridization temperature (T_h) is approximately 20 to 40°C, 20 to 25°C, or, preferably 30 to 40°C below the calculated T_m . Those skilled in the art will understand that optimal temperature and salt conditions can be readily determined.

For the polynucleotides of the invention, stringent conditions are achieved for both pre-hybridizing and hybridizing incubations (i) within 4-16 hours at 42°C, in 6 x SSC containing 50% formamide, or (ii) within 4-16 hours at 65°C in an aqueous 6 x SSC solution (1 M NaCl, 0.1 M sodium citrate (pH 7.0)). Typically, hybridization experiments are performed at a temperature from 60 to 68°C, e.g. 65°C. At such a temperature, stringent hybridization conditions can be achieved in 6xSSC, preferably in 2xSSC or 1xSSC, more preferably in 0.5xSSC, 0.3xSSC or 0.1xSSC (in the absence of formamide). 1xSSC contains 0.15 M NaCl and 0.015 M sodium citrate.

Useful homologs and fragments thereof that do not occur naturally are designed using known methods for identifying regions of an antigen that are likely to tolerate amino acid sequence changes and/or deletions. As an example, homologous polypeptides from different species are compared; conserved sequences are identified. The more divergent sequences are the most likely to tolerate sequence changes. Homology among sequences may be analyzed using, as an example, the BLAST homology searching algorithm of Altschul et al.,

Nucleic Acids Res.; 25:3389-3402 (1997). Alternatively, sequences are modified such that they become more reactive to T- and/or B-cells, based on computer-assisted analysis of probable T- or B-cell epitopes. Yet another alternative is to
5 mutate a particular amino acid residue or sequence within the polypeptide *in vitro*, then screen the mutant polypeptides for their ability to prevent or treat *Chlamydia* infection according to the method outlined below.

A person skilled in the art will readily understand
10 that by following the screening process of this invention, it will be determined without undue experimentation whether a particular homolog of SEQ ID No. 2 may be useful in the prevention or treatment of *Chlamydia* infection. The screening procedure comprises the steps:

- 15 (i) immunizing an animal, preferably mouse, with the test homolog or fragment;
- (ii) inoculating the immunized animal with *Chlamydia*; and
- (iii) selecting those homologs or fragments which
20 confer protection against *Chlamydia*.

By "conferring protection" is meant that there is a reduction in severity of any of the effects of *Chlamydia* infection, in comparison with a control animal which was not immunized with the test homolog or fragment.

25 Consistent with the first aspect of the invention, polypeptide derivatives are provided that are partial sequences of SEQ ID No. 2, partial sequences of polypeptide sequences homologous to SEQ ID No. 2, polypeptides derived from full-length polypeptides by internal deletion, and fusion proteins.

30 It is an accepted practice in the field of immunology to use fragments and variants of protein immunogens as vaccines, as all that is required to induce an immune response to a protein is a small (e.g., 8 to 10 amino acid) immunogenic region of the protein. Various short synthetic peptides

corresponding to surface-exposed antigens of pathogens other than *Chlamydia* have been shown to be effective vaccine antigens against their respective pathogens, e.g. an 11 residue peptide of murine mammary tumor virus (Casey & Davidson, Nucl. Acid
5 Res. (1977) 4:1539), a 16-residue peptide of Semliki Forest virus (Snijders et al., 1991. J. Gen. Virol. 72:557-565), and two overlapping peptides of 15 residues each from canine parvovirus (Langeveld et al., Vaccine 12(15):1473-1480, 1994).

Accordingly, it will be readily apparent to one
10 skilled in the art, having read the present description, that partial sequences of SEQ ID No: 2 or their homologous amino acid sequences are inherent to the full-length sequences and are taught by the present invention. Such polypeptide fragments preferably are at least 12 amino acids in length.
15 Advantageously, they are at least 20 amino acids, preferably at least 50 amino acids, more preferably at least 75 amino acids, and most preferably at least 100 amino acids in length.

Polynucleotides of 30 to 600 nucleotides encoding partial sequences of sequences homologous to SEQ ID No: 2 are
20 retrieved by PCR amplification using the parameters outlined above and using primers matching the sequences upstream and downstream of the 5' and 3' ends of the fragment to be amplified. The template polynucleotide for such amplification is either the full length polynucleotide homologous to SEQ ID
25 No: 1, or a polynucleotide contained in a mixture of polynucleotides such as a DNA or RNA library. As an alternative method for retrieving the partial sequences, screening hybridization is carried out under conditions described above and using the formula for calculating T_m .

30 Where fragments of 30 to 600 nucleotides are to be retrieved, the calculated T_m is corrected by subtracting (600/polynucleotide size in base pairs) and the stringency conditions are defined by a hybridization temperature that is 5 to 10°C below T_m . Where oligonucleotides shorter than 20-30

bases are to be obtained, the formula for calculating the T_m is as follows: $T_m = 4 \times (G+C) + 2 \times (A+T)$. For example, an 18 nucleotide fragment of 50% G+C would have an approximate T_m of 54°C. Short peptides that are fragments of SEQ ID No: 2 or its homologous sequences, are obtained directly by chemical synthesis (E. Gross and H. J. Meinhofer, 4 The Peptides: Analysis, Synthesis, Biology; Modern Techniques of Peptide Synthesis, John Wiley & Sons (1981), and M. Bodanzki, Principles of Peptide Synthesis, Springer -Verlag (1984)).

Useful polypeptide derivatives, e.g., polypeptide fragments, are designed using computer-assisted analysis of amino acid sequences. This would identify probable surface-exposed, antigenic regions (Hughes et al., 1992. Infect. Immun. 60(9):3497). Analysis of 6 amino acid sequences contained in SEQ ID No: 2, based on the product of flexibility and hydrophobicity propensities using the program SEQSEE (Wishart DS, et al. "SEQSEE: a comprehensive program suite for protein sequence analysis." *Comput Appl Biosci*. 1994 Apr;10(2):121-32), can reveal potential B- and T-cell epitopes which may be used as a basis for selecting useful immunogenic fragments and variants. This analysis uses a reasonable combination of external surface features that is likely to be recognized by antibodies. Probable T-cell epitopes for HLA-A0201 MHC subclass may be revealed by an algorithms that emulate an approach developed at the NIH (Parker KC, et al. "Peptide binding to MHC class I molecules: implications for antigenic peptide prediction." *Immunol Res* 1995;14(1):34-57).

Epitopes which induce a protective T cell-dependent immune response are present throughout the length of the polypeptide. However, some epitopes may be masked by secondary and tertiary structures of the polypeptide. To reveal such masked epitopes large internal deletions are created which remove much of the original protein structure and exposes the masked epitopes. Such internal deletions sometimes effect the

additional advantage of removing immunodominant regions of high variability among strains.

Polynucleotides encoding polypeptide fragments and polypeptides having large internal deletions are constructed using standard methods (Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994). Such methods include standard PCR, inverse PCR, restriction enzyme treatment of cloned DNA molecules, or the method of Kunkel et al. (Kunkel et al. Proc. Natl. Acad. Sci. USA (1985) 82:448).

Components for these methods and instructions for their use are readily available from various commercial sources such as Stratagene. Once the deletion mutants have been constructed, they are tested for their ability to prevent or treat *Chlamydia* infection as described above.

As used herein, a fusion polypeptide is one that contains a polypeptide or a polypeptide derivative of the invention fused at the N- or C-terminal end to any other polypeptide (hereinafter referred to as a peptide tail). A simple way to obtain such a fusion polypeptide is by translation of an in-frame fusion of the polynucleotide sequences, i.e., a hybrid gene. The hybrid gene encoding the fusion polypeptide is inserted into an expression vector which is used to transform or transfect a host cell. Alternatively, the polynucleotide sequence encoding the polypeptide or polypeptide derivative is inserted into an expression vector in which the polynucleotide encoding the peptide tail is already present. Such vectors and instructions for their use are commercially available, e.g. the pMal-c2 or pMal-p2 system from New England Biolabs, in which the peptide tail is a maltose binding protein, the glutathione-S-transferase system of Pharmacia, or the His-Tag system available from Novagen. These and other expression systems provide convenient means for further purification of polypeptides and derivatives of the invention.

An advantageous example of a fusion polypeptide is one where the polypeptide or homolog or fragment of the invention is fused to a polypeptide having adjuvant activity, such as subunit B of either cholera toxin or *E. coli* heat-labile toxin. Another advantageous fusion is one where the polypeptide, homolog or fragment is fused to a strong T-cell epitope or B-cell epitope. Such an epitope may be one known in the art (e.g. the Hepatitis B virus core antigen, D.R. Millich et al., "Antibody production to the nucleocapsid and envelope of the Hepatitis B virus primed by a single synthetic T cell site", Nature. 1987. 329:547-549), or one which has been identified in another polypeptide of the invention based on computer-assisted analysis of probable T- or B-cell epitopes. Consistent with this aspect of the invention is a fusion polypeptide comprising T- or B-cell epitopes from SEQ ID No: 2 or its homolog or fragment, wherein the epitopes are derived from multiple variants of said polypeptide or homolog or fragment, each variant differing from another in the location and sequence of its epitope within the polypeptide. Such a fusion is effective in the prevention and treatment of *Chlamydia* infection since it optimizes the T- and B-cell response to the overall polypeptide, homolog or fragment.

To effect fusion, the polypeptide of the invention is fused to the N-, or preferably, to the C-terminal end of the polypeptide having adjuvant activity or T- or B-cell epitope. Alternatively, a polypeptide fragment of the invention is inserted internally within the amino acid sequence of the polypeptide having adjuvant activity. The T- or B-cell epitope may also be inserted internally within the amino acid sequence of the polypeptide of the invention.

Consistent with the first aspect, the polynucleotides of the invention also encode hybrid precursor polypeptides containing heterologous signal peptides, which mature into polypeptides of the invention. By "heterologous signal

peptide" is meant a signal peptide that is not found in naturally-occurring precursors of polypeptides of the invention.

Polynucleotide molecules according to the invention, including RNA, DNA, or modifications or combinations thereof, have various applications. A DNA molecule is used, for example, (i) in a process for producing the encoded polypeptide in a recombinant host system, (ii) in the construction of vaccine vectors such as poxviruses, which are further used in methods and compositions for preventing and/or treating *Chlamydia* infection, (iii) as a vaccine agent (as well as an RNA molecule), in a naked form or formulated with a delivery vehicle and, (iv) in the construction of attenuated *Chlamydia* strains that can over-express a polynucleotide of the invention or express it in a non-toxic, mutated form.

Accordingly, a second aspect of the invention encompasses (i) an expression cassette containing a DNA molecule of the invention placed under the control of the elements required for expression, in particular under the control of an appropriate promoter; (ii) an expression vector containing an expression cassette of the invention; (iii) a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, as well as (iv) a process for producing a polypeptide or polypeptide derivative encoded by a polynucleotide of the invention, which involves culturing a procaryotic or eucaryotic cell transformed or transfected with an expression cassette and/or vector of the invention, under conditions that allow expression of the DNA molecule of the invention and, recovering the encoded polypeptide or polypeptide derivative from the cell culture.

A recombinant expression system is selected from procaryotic and eucaryotic hosts. Eucaryotic hosts include yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris*), mammalian cells (e.g., COS1, NIH3T3, or JEG3 cells),

arthropods cells (e.g., *Spodoptera frugiperda* (SF9) cells), and plant cells. A preferred expression system is a procaryotic host such as *E. coli*. Bacterial and eucaryotic cells are available from a number of different sources including commercial sources to those skilled in the art, e.g., the American Type Culture Collection (ATCC; Rockville, Maryland). Commercial sources of cells used for recombinant protein expression also provide instructions for usage of the cells.

The choice of the expression system depends on the features desired for the expressed polypeptide. For example, it may be useful to produce a polypeptide of the invention in a particular lipidated form or any other form.

One skilled in the art would readily understand that not all vectors and expression control sequences and hosts would be expected to express equally well the polynucleotides of this invention. With the guidelines described below, however, a selection of vectors, expression control sequences and hosts may be made without undue experimentation and without departing from the scope of this invention.

In selecting a vector, the host must be chosen that is compatible with the vector which is to exist and possibly replicate in it. Considerations are made with respect to the vector copy number, the ability to control the copy number, expression of other proteins such as antibiotic resistance. In selecting an expression control sequence, a number of variables are considered. Among the important variable are the relative strength of the sequence (e.g. the ability to drive expression under various conditions), the ability to control the sequence's function, compatibility between the polynucleotide to be expressed and the control sequence (e.g. secondary structures are considered to avoid hairpin structures which prevent efficient transcription). In selecting the host, unicellular hosts are selected which are compatible with the selected vector, tolerant of any possible toxic effects of the

expressed product, able to secrete the expressed product efficiently if such is desired, to be able to express the product in the desired conformation, to be easily scaled up, and to which ease of purification of the final product.

5 The choice of the expression cassette depends on the host system selected as well as the features desired for the expressed polypeptide. Typically, an expression cassette includes a promoter that is functional in the selected host system and can be constitutive or inducible; a ribosome binding
10 site; a start codon (ATG) if necessary; a region encoding a signal peptide, e.g., a lipidation signal peptide; a DNA molecule of the invention; a stop codon; and optionally a 3' terminal region (translation and/or transcription terminator). The signal peptide encoding region is adjacent to the
15 polynucleotide of the invention and placed in proper reading frame. The signal peptide-encoding region is homologous or heterologous to the DNA molecule encoding the mature polypeptide and is compatible with the secretion apparatus of the host used for expression. The open reading frame
20 constituted by the DNA molecule of the invention, solely or together with the signal peptide, is placed under the control of the promoter so that transcription and translation occur in the host system. Promoters and signal peptide encoding regions are widely known and available to those skilled in the art and
25 include, for example, the promoter of *Salmonella typhimurium* (and derivatives) that is inducible by arabinose (promoter araB) and is functional in Gram-negative bacteria such as *E. coli* (as described in U.S. Patent No. 5,028,530 and in Cagnon et al., (Cagnon et al., Protein Engineering (1991) 4(7):843));
30 the promoter of the gene of bacteriophage T7 encoding RNA polymerase, that is functional in a number of *E. coli* strains expressing T7 polymerase (described in U.S. Patent No. 4,952,496); OspA lipidation signal peptide ; and RlpB

lipidation signal peptide (Takase et al., J. Bact. (1987) 169:5692).

The expression cassette is typically part of an expression vector, which is selected for its ability to replicate in the chosen expression system. Expression vectors (e.g., plasmids or viral vectors) can be chosen, for example, from those described in Pouwels et al. (Cloning Vectors: A Laboratory Manual 1985, Supp. 1987). Suitable expression vectors can be purchased from various commercial sources.

Methods for transforming/transfecting host cells with expression vectors are well-known in the art and depend on the host system selected as described in Ausubel et al., (Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994).

Upon expression, a recombinant polypeptide of the invention (or a polypeptide derivative) is produced and remains in the intracellular compartment, is secreted/excreted in the extracellular medium or in the periplasmic space, or is embedded in the cellular membrane. The polypeptide is recovered in a substantially purified form from the cell extract or from the supernatant after centrifugation of the recombinant cell culture. Typically, the recombinant polypeptide is purified by antibody-based affinity purification or by other well-known methods that can be readily adapted by a person skilled in the art, such as fusion of the polynucleotide encoding the polypeptide or its derivative to a small affinity binding domain. Antibodies useful for purifying by immunoaffinity the polypeptides of the invention are obtained as described below.

A polynucleotide of the invention can also be useful as a vaccine. There are two major routes, either using a viral or bacterial host as gene delivery vehicle (live vaccine vector) or administering the gene in a free form, e.g., inserted into a plasmid. Therapeutic or prophylactic efficacy

of a polynucleotide of the invention is evaluated as described below.

Accordingly, a third aspect of the invention provides (i) a vaccine vector such as a poxvirus, containing a DNA molecule of the invention, placed under the control of elements required for expression; (ii) a composition of matter comprising a vaccine vector of the invention, together with a diluent or carrier; specifically (iii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a vaccine vector of the invention; (iv) a method for inducing an immune response against *Chlamydia* in a mammal (e.g., a human; alternatively, the method can be used in veterinary applications for treating or preventing *Chlamydia* infection of animals, e.g., cats or birds), which involves administering to the mammal an immunogenically effective amount of a vaccine vector of the invention to elicit a protective or therapeutic immune response to *Chlamydia* ; and particularly, (v) a method for preventing and/or treating a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumonia*, *C. pecorum*) infection, which involves administering a prophylactic or therapeutic amount of a vaccine vector of the invention to an infected individual. Additionally, the third aspect of the invention encompasses the use of a vaccine vector of the invention in the preparation of a medicament for preventing and/or treating *Chlamydia* infection.

As used herein, a vaccine vector expresses one or several polypeptides or derivatives of the invention. The vaccine vector may express additionally a cytokine, such as interleukin-2 (IL-2) or interleukin-12 (IL-12), that enhances the immune response (adjuvant effect). It is understood that each of the components to be expressed is placed under the control of elements required for expression in a mammalian cell.

Consistent with the third aspect of the invention is a composition comprising several vaccine vectors, each of them capable of expressing a polypeptide or derivative of the invention. A composition may also comprise a vaccine vector
5 capable of expressing an additional *Chlamydia* antigen, or a subunit, fragment, homolog, mutant, or derivative thereof; optionally together with or a cytokine such as IL-2 or IL-12.

Vaccination methods for treating or preventing infection in a mammal comprises use of a vaccine vector of the
10 invention to be administered by any conventional route, particularly to a mucosal (e.g., ocular, intranasal, oral, gastric, pulmonary, intestinal, rectal, vaginal, or urinary tract) surface or via the parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal)
15 route. Preferred routes depend upon the choice of the vaccine vector. Treatment may be effected in a single dose or repeated at intervals. The appropriate dosage depends on various parameters understood by skilled artisans such as the vaccine vector itself, the route of administration or the condition of
20 the mammal to be vaccinated (weight, age and the like).

Live vaccine vectors available in the art include viral vectors such as adenoviruses and poxviruses as well as bacterial vectors, e.g., *Shigella*, *Salmonella*, *Vibrio cholerae*, *Lactobacillus*, Bacille bilié de Calmette-Guérin (BCG), and
25 *Streptococcus*.

An example of an adenovirus vector, as well as a method for constructing an adenovirus vector capable of expressing a DNA molecule of the invention, are described in U.S. Patent No. 4,920,209. Poxvirus vectors include vaccinia
30 and canary pox virus, described in U.S. Patent No. 4,722,848 and U.S. Patent No. 5,364,773, respectively. (Also see, e.g., Tartaglia et al., Virology (1992) 188:217) for a description of a vaccinia virus vector and Taylor et al, Vaccine (1995) 13:539 for a reference of a canary pox.) Poxvirus vectors capable of

expressing a polynucleotide of the invention are obtained by homologous recombination as described in Kieny et al., Nature (1984) 312:163 so that the polynucleotide of the invention is inserted in the viral genome under appropriate conditions for expression in mammalian cells. Generally, the dose of vaccine viral vector, for therapeutic or prophylactic use, can be of from about 1×10^4 to about 1×10^{11} , advantageously from about 1×10^7 to about 1×10^{10} , preferably of from about 1×10^7 to about 1×10^9 plaque-forming units per kilogram. Preferably, viral vectors are administered parenterally; for example, in 3 doses, 4 weeks apart. It is preferable to avoid adding a chemical adjuvant to a composition containing a viral vector of the invention and thereby minimizing the immune response to the viral vector itself.

Non-toxicogenic *Vibrio cholerae* mutant strains that are useful as a live oral vaccine are known. Mekalanos et al., Nature (1983) 306:551 and U.S. Patent No. 4,882,278 describe strains which have a substantial amount of the coding sequence of each of the two *ctxA* alleles deleted so that no functional *cholerae* toxin is produced. WO 92/11354 describes a strain in which the *irgA* locus is inactivated by mutation; this mutation can be combined in a single strain with *ctxA* mutations. WO 94/01533 describes a deletion mutant lacking functional *ctxA* and *attRS1* DNA sequences. These mutant strains are genetically engineered to express heterologous antigens, as described in WO 94/19482. An effective vaccine dose of a *Vibrio cholerae* strain capable of expressing a polypeptide or polypeptide derivative encoded by a DNA molecule of the invention contains about 1×10^5 to about 1×10^9 , preferably about 1×10^6 to about 1×10^8 , viable bacteria in a volume appropriate for the selected route of administration. Preferred routes of administration include all mucosal routes; most preferably, these vectors are administered intranasally or orally.

Attenuated *Salmonella typhimurium* strains, genetically engineered for recombinant expression of heterologous antigens or not, and their use as oral vaccines are described in Nakayama et al. (Bio/Technology (1988) 6:693) and WO 92/11361. Preferred routes of administration include all mucosal routes; most preferably, these vectors are administered intranasally or orally.

Other bacterial strains used as vaccine vectors in the context of the present invention are described for *Shigella flexneri* in High et al., EMBO (1992) 11:1991 and Sizemore et al., Science (1995) 270:299; for *Streptococcus gordonii* in Medaglini et al., Proc. Natl. Acad. Sci. USA (1995) 92:6868; and for Bacille Calmette Guerin in Flynn J.L., Cell. Mol. Biol. (1994) 40 (suppl. I):31, WO 88/06626, WO 90/00594, WO 91/13157, WO 92/01796, and WO 92/21376.

In bacterial vectors, the polynucleotide of the invention is inserted into the bacterial genome or remains in a free state as part of a plasmid.

The composition comprising a vaccine bacterial vector of the present invention may further contain an adjuvant. A number of adjuvants are known to those skilled in the art. Preferred adjuvants are selected as provided below.

Accordingly, a fourth aspect of the invention provides (i) a composition of matter comprising a polynucleotide of the invention, together with a diluent or carrier; (ii) a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a polynucleotide of the invention; (iii) a method for inducing an immune response against *Chlamydia* in a mammal by administration of an immunogenically effective amount of a polynucleotide of the invention to elicit a protective immune response to *Chlamydia*; and particularly, (iv) a method for preventing and/or treating a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae*, or *C. pecorum*) infection, by administering a

prophylactic or therapeutic amount of a polynucleotide of the invention to an infected individual. Additionally, the fourth aspect of the invention encompasses the use of a polynucleotide of the invention in the preparation of a medicament for preventing and/or treating *Chlamydia* infection. A preferred use includes the use of a DNA molecule placed under conditions for expression in a mammalian cell, especially in a plasmid that is unable to replicate in mammalian cells and to substantially integrate in a mammalian genome.

Use of the polynucleotides of the invention include their administration to a mammal as a vaccine, for therapeutic or prophylactic purposes. Such polynucleotides are used in the form of DNA as part of a plasmid that is unable to replicate in a mammalian cell and unable to integrate into the mammalian genome. Typically, such a DNA molecule is placed under the control of a promoter suitable for expression in a mammalian cell. The promoter functions either ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early Cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (described in Norton & Coffin, *Molec. Cell Biol.* (1985) 5:281). An example of a tissue-specific promoter is the desmin promoter which drives expression in muscle cells (Li et al., *Gene* (1989) 78:243, Li & Paulin, *J. Biol. Chem.* (1991) 266:6562 and Li & Paulin, *J. Biol. Chem.* (1993) 268:10403). Use of promoters is well-known to those skilled in the art. Useful vectors are described in numerous publications, specifically WO 94/21797 and Hartikka et al., *Human Gene Therapy* (1996) 7:1205.

Polynucleotides of the invention which are used as vaccines encode either a precursor or a mature form of the corresponding polypeptide. In the precursor form, the signal peptide is either homologous or heterologous. In the latter case, a eucaryotic leader sequence such as the leader sequence of the tissue-type plasminogen factor (tPA) is preferred.

As used herein, a composition of the invention contains one or several polynucleotides with optionally at least one additional polynucleotide encoding another *Chlamydia* antigen such as urease subunit A, B, or both, or a fragment, derivative, mutant, or analog thereof. The composition may also contain an additional polynucleotide encoding a cytokine, such as interleukin-2 (IL-2) or interleukin-12 (IL-12) so that the immune response is enhanced. These additional polynucleotides are placed under appropriate control for expression. Advantageously, DNA molecules of the invention and/or additional DNA molecules to be included in the same composition, are present in the same plasmid.

Standard techniques of molecular biology for preparing and purifying polynucleotides are used in the preparation of polynucleotide therapeutics of the invention. For use as a vaccine, a polynucleotide of the invention is formulated according to various methods outlined below.

One method utilizes the polynucleotide in a naked form, free of any delivery vehicles. Such a polynucleotide is simply diluted in a physiologically acceptable solution such as sterile saline or sterile buffered saline, with or without a carrier. When present, the carrier preferably is isotonic, hypotonic, or weakly hypertonic, and has a relatively low ionic strength, such as provided by a sucrose solution, e.g., a solution containing 20% sucrose.

An alternative method utilizes the polynucleotide in association with agents that assist in cellular uptake. Examples of such agents are (i) chemicals that modify cellular permeability, such as bupivacaine (see, e.g., WO 94/16737), (ii) liposomes for encapsulation of the polynucleotide, or (iii) cationic lipids or silica, gold, or tungsten microparticles which associate themselves with the polynucleotides.

Anionic and neutral liposomes are well-known in the art (see, e.g., Liposomes: A Practical Approach, RPC New Ed, IRL press (1990), for a detailed description of methods for making liposomes) and are useful for delivering a large range of products, including polynucleotides.

Cationic lipids are also known in the art and are commonly used for gene delivery. Such lipids include LipofectinTM also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidoglycyl spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol). A description of these cationic lipids can be found in EP 187,702, WO 90/11092, U.S. Patent No. 5,283,185, WO 91/15501, WO 95/26356, and U.S. Patent No. 5,527,928. Cationic lipids for gene delivery are preferably used in association with a neutral lipid such as DOPE (dioleoyl phosphatidylethanolamine), as described in WO 90/11092 as an example.

Formulation containing cationic liposomes may optionally contain other transfection-facilitating compounds. A number of them are described in WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/02397. They include spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 93/19768).

Gold or tungsten microparticles are used for gene delivery, as described in WO 91/00359, WO 93/17706, and Tang et al. Nature (1992) 356:152. The microparticle-coated polynucleotide is injected via intradermal or intraepidermal routes using a needleless injection device ("gene gun"), such as those described in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263.

The amount of DNA to be used in a vaccine recipient depends, e.g., on the strength of the promoter used in the DNA construct, the immunogenicity of the expressed gene product, the condition of the mammal intended for administration (e.g.,
5 the weight, age, and general health of the mammal), the mode of administration, and the type of formulation. In general, a therapeutically or prophylactically effective dose from about 1 μ g to about 1 mg, preferably, from about 10 μ g to about 800 μ g and, more preferably, from about 25 μ g to about 250 μ g, can
10 be administered to human adults. The administration can be achieved in a single dose or repeated at intervals.

The route of administration is any conventional route used in the vaccine field. As general guidance, a polynucleotide of the invention is administered via a mucosal
15 surface, e.g., an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface; or via a parenteral route, e.g., by an intravenous, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route. The choice of administration route depends on the
20 formulation that is selected. A polynucleotide formulated in association with bupivacaine is advantageously administered into muscles. When a neutral or anionic liposome or a cationic lipid, such as DOTMA or DC-Chol, is used, the formulation can be advantageously injected via intravenous, intranasal
25 (aerosolization), intramuscular, intradermal, and subcutaneous routes. A polynucleotide in a naked form can advantageously be administered via the intramuscular, intradermal, or subcutaneous routes.

Although not absolutely required, such a composition
30 can also contain an adjuvant. If so, a systemic adjuvant that does not require concomitant administration in order to exhibit an adjuvant effect is preferable such as, e.g., QS21, which is described in U.S. Patent No. 5,057,546.

The sequence information provided in the present application enables the design of specific nucleotide probes and primers that are used for diagnostic purposes.

Accordingly, a fifth aspect of the invention provides a
5 nucleotide probe or primer having a sequence found in or derived by degeneracy of the genetic code from a sequence shown in SEQ ID No:1.

The term "probe" as used in the present application refers to DNA (preferably single stranded) or RNA molecules (or
10 modifications or combinations thereof) that hybridize under the stringent conditions, as defined above, to nucleic acid molecules having SEQ ID No:1 or to sequences homologous to SEQ ID No:1, or to its complementary or anti-sense sequence. Generally, probes are significantly shorter than full-length
15 sequences. Such probes contain from about 5 to about 100, preferably from about 10 to about 80, nucleotides. In particular, probes have sequences that are at least 75%, preferably at least 85%, more preferably 95% homologous to a portion of SEQ ID No:1 or that are complementary to such
20 sequences. Probes may contain modified bases such as inosine, methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, or diamino-2, 6-purine. Sugar or phosphate residues may also be modified or substituted. For example, a deoxyribose residue may be replaced by a polyamide (Nielsen
25 et al., Science (1991) 254:1497) and phosphate residues may be replaced by ester groups such as diphosphate, alkyl, arylphosphonate and phosphorothioate esters. In addition, the 2'-hydroxyl group on ribonucleotides may be modified by including such groups as alkyl groups.

30 Probes of the invention are used in diagnostic tests, as capture or detection probes. Such capture probes are conventionally immobilized on a solid support, directly or indirectly, by covalent means or by passive adsorption. A detection probe is labelled by a detection marker selected

from: radioactive isotopes, enzymes such as peroxidase, alkaline phosphatase, and enzymes able to hydrolyze a chromogenic, fluorogenic, or luminescent substrate, compounds that are chromogenic, fluorogenic, or luminescent, nucleotide
5 base analogs, and biotin.

Probes of the invention are used in any conventional hybridization technique, such as dot blot (Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York),
10 Southern blot (Southern, J. Mol. Biol. (1975) 98:503), northern blot (identical to Southern blot with the exception that RNA is used as a target), or the sandwich technique (Dunn et al., Cell (1977) 12:23). The latter technique involves the use of a specific capture probe and/or a specific detection probe with
15 nucleotide sequences that at least partially differ from each other.

A primer is a probe of usually about 10 to about 40 nucleotides that is used to initiate enzymatic polymerization of DNA in an amplification process (e.g., PCR),
20 in an elongation process, or in a reverse transcription method. Primers used in diagnostic methods involving PCR are labeled by methods known in the art.

As described herein, the invention also encompasses (i) a reagent comprising a probe of the invention for detecting
25 and/or identifying the presence of *Chlamydia* in a biological material; (ii) a method for detecting and/or identifying the presence of *Chlamydia* in a biological material, in which (a) a sample is recovered or derived from the biological material, (b) DNA or RNA is extracted from the material and denatured,
30 and (c) exposed to a probe of the invention, for example, a capture, detection probe or both, under stringent hybridization conditions, such that hybridization is detected; and (iii) a method for detecting and/or identifying the presence of *Chlamydia* in a biological material, in which (a) a sample is

recovered or derived from the biological material, (b) DNA is extracted therefrom, (c) the extracted DNA is primed with at least one, and preferably two, primers of the invention and amplified by polymerase chain reaction, and (d) the amplified
5 DNA fragment is produced.

It is apparent that disclosure of polynucleotide sequences of SEQ ID No:1, its homologs and partial sequences enable their corresponding amino acid sequences. Accordingly, a sixth aspect of the invention features a substantially
10 purified polypeptide or polypeptide derivative having an amino acid sequence encoded by a polynucleotide of the invention.

A "substantially purified polypeptide" as used herein is defined as a polypeptide that is separated from the environment in which it naturally occurs and/or that is free of
15 the majority of the polypeptides that are present in the environment in which it was synthesized. For example, a substantially purified polypeptide is free from cytoplasmic polypeptides. Those skilled in the art would readily understand that the polypeptides of the invention may be
20 purified from a natural source, *i.e.*, a *Chlamydia* strain, or produced by recombinant means.

Consistent with the sixth aspect of the invention are polypeptides, homologs or fragments which are modified or treated to enhance their immunogenicity in the target animal,
25 in whom the polypeptide, homolog or fragments are intended to confer protection against *Chlamydia*. Such modifications or treatments include: amino acid substitutions with an amino acid derivative such as 3-methylhistidine, 4-hydroxyproline, 5-hydroxylysine etc., modifications or deletions which are
30 carried out after preparation of the polypeptide, homolog or fragment, such as the modification of free amino, carboxyl or hydroxyl side groups of the amino acids.

Identification of homologous polypeptides or polypeptide derivatives encoded by polynucleotides of the

invention which have specific antigenicity is achieved by screening for cross-reactivity with an antiserum raised against the polypeptide of reference having an amino acid sequence of SEQ ID No:1. The procedure is as follows: a monospecific
5 hyperimmune antiserum is raised against a purified reference polypeptide, a fusion polypeptide (for example, an expression product of MBP, GST, or His-tag systems, the description and instructions for use of which are contained in Invitrogen product manuals for pCDNA3.1/Myc-His(+) A, B, and C and for the
10 Xpress[™] System Protein Purification), or a synthetic peptide predicted to be antigenic. Where an antiserum is raised against a fusion polypeptide, two different fusion systems are employed. Specific antigenicity can be determined according to a number of methods, including Western blot (Towbin et al.,
15 Proc. Natl. Acad. Sci. USA (1979) 76:4350), dot blot, and ELISA, as described below.

In a Western blot assay, the product to be screened, either as a purified preparation or a total *E. coli* extract, is submitted to SDS-Page electrophoresis as described by Laemmli
20 (Nature (1970) 227:680). After transfer to a nitrocellulose membrane, the material is further incubated with the monospecific hyperimmune antiserum diluted in the range of dilutions from about 1:5 to about 1:5000, preferably from about 1:100 to about 1:500. Specific antigenicity is shown once a
25 band corresponding to the product exhibits reactivity at any of the dilutions in the above range.

In an ELISA assay, the product to be screened is preferably used as the coating antigen. A purified preparation is preferred, although a whole cell extract can also be used.
30 Briefly, about 100 μ l of a preparation at about 10 μ g protein/ml are distributed into wells of a 96-well polycarbonate ELISA plate. The plate is incubated for 2 hours at 37°C then overnight at 4°C. The plate is washed with phosphate buffer saline (PBS) containing 0.05% Tween 20

(PBS/Tween buffer). The wells are saturated with 250 μ l PBS containing 1% bovine serum albumin (BSA) to prevent non-specific antibody binding. After 1 hour incubation at 37°C, the plate is washed with PBS/Tween buffer. The antiserum is serially diluted in PBS/Tween buffer containing 0.5% BSA. 100 μ l of dilutions are added per well. The plate is incubated for 90 minutes at 37°C, washed and evaluated according to standard procedures. For example, a goat anti-rabbit peroxidase conjugate is added to the wells when specific antibodies were raised in rabbits. Incubation is carried out for 90 minutes at 37°C and the plate is washed. The reaction is developed with the appropriate substrate and the reaction is measured by colorimetry (absorbance measured spectrophotometrically). Under the above experimental conditions, a positive reaction is shown by O.D. values greater than a non immune control serum.

In a dot blot assay, a purified product is preferred, although a whole cell extract can also be used. Briefly, a solution of the product at about 100 μ g/ml is serially two-fold diluted in 50 mM Tris-HCl (pH 7.5). 100 μ l of each dilution are applied to a nitrocellulose membrane 0.45 μ m set in a 96-well dot blot apparatus (Biorad). The buffer is removed by applying vacuum to the system. Wells are washed by addition of 50 mM Tris-HCl (pH 7.5) and the membrane is air-dried. The membrane is saturated in blocking buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10 g/L skim milk) and incubated with an antiserum dilution from about 1:50 to about 1:5000, preferably about 1:500. The reaction is revealed according to standard procedures. For example, a goat anti-rabbit peroxidase conjugate is added to the wells when rabbit antibodies are used. Incubation is carried out 90 minutes at 37°C and the blot is washed. The reaction is developed with the appropriate substrate and stopped. The reaction is measured visually by the appearance of a colored spot, e.g., by colorimetry. Under the above experimental conditions, a positive reaction is shown

once a colored spot is associated with a dilution of at least about 1:5, preferably of at least about 1:500.

Therapeutic or prophylactic efficacy of a polypeptide or derivative of the invention can be evaluated as described
5 below. A seventh aspect of the invention provides (i) a composition of matter comprising a polypeptide of the invention together with a diluent or carrier; specifically (ii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a polypeptide of the
10 invention; (iii) a method for inducing an immune response against *Chlamydia* in a mammal, by administering to the mammal an immunogenically effective amount of a polypeptide of the invention to elicit a protective immune response to *Chlamydia*; and particularly, (iv) a method for preventing and/or treating
15 a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae*, or *C. pecorum*) infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to an infected individual. Additionally, the seventh aspect of the invention encompasses the use of a polypeptide of the invention
20 in the preparation of a medicament for preventing and/or treating *Chlamydia* infection.

As used herein, the immunogenic compositions of the invention are administered by conventional routes known the vaccine field, in particular to a mucosal (e.g., ocular,
25 intranasal, pulmonary, oral, gastric, intestinal, rectal, vaginal, or urinary tract) surface or via the parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal) route. The choice of administration route depends upon a number of parameters, such as the adjuvant
30 associated with the polypeptide. If a mucosal adjuvant is used, the intranasal or oral route is preferred. If a lipid formulation or an aluminum compound is used, the parenteral route is preferred with the sub-cutaneous or intramuscular route being most preferred. The choice also depends upon the

nature of the vaccine agent. For example, a polypeptide of the invention fused to CTB or LTB is best administered to a mucosal surface.

As used herein, the composition of the invention
5 contains one or several polypeptides or derivatives of the invention. The composition optionally contains at least one additional *Chlamydia* antigen, or a subunit, fragment, homolog, mutant, or derivative thereof.

For use in a composition of the invention, a
10 polypeptide or derivative thereof is formulated into or with liposomes, preferably neutral or anionic liposomes, microspheres, ISCOMS, or virus-like-particles (VLPs) to facilitate delivery and/or enhance the immune response. These compounds are readily available to one skilled in the art; for
15 example, see Liposomes: A Practical Approach, RCP New Ed, IRL press (1990).

Adjuvants other than liposomes and the like are also used and are known in the art. Adjuvants may protect the antigen from rapid dispersal by sequestering it in a local
20 deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system. An appropriate selection can conventionally be made by those skilled in the art, for example, from those described below (under the
25 eleventh aspect of the invention).

Treatment is achieved in a single dose or repeated as necessary at intervals, as can be determined readily by one skilled in the art. For example, a priming dose is followed by three booster doses at weekly or monthly intervals. An
30 appropriate dose depends on various parameters including the recipient (e.g., adult or infant), the particular vaccine antigen, the route and frequency of administration, the presence/absence or type of adjuvant, and the desired effect (e.g., protection and/or treatment), as can be determined by

one skilled in the art. In general, a vaccine antigen of the invention is administered by a mucosal route in an amount from about 10 μ g to about 500 mg, preferably from about 1 mg to about 200 mg. For the parenteral route of administration, the
5 dose usually does not exceed about 1 mg, preferably about 100 μ g.

When used as vaccine agents, polynucleotides and polypeptides of the invention may be used sequentially as part of a multistep immunization process. For example, a mammal is
10 initially primed with a vaccine vector of the invention such as a pox virus, e.g., via the parenteral route, and then boosted twice with the polypeptide encoded by the vaccine vector, e.g., via the mucosal route. In another example, liposomes associated with a polypeptide or derivative of the invention is
15 also used for priming, with boosting being carried out mucosally using a soluble polypeptide or derivative of the invention in combination with a mucosal adjuvant (e.g., LT).

A polypeptide derivative of the invention is also used in accordance with the seventh aspect as a diagnostic
20 reagent for detecting the presence of anti-*Chlamydia* antibodies, e.g., in a blood sample. Such polypeptides are about 5 to about 80, preferably about 10 to about 50 amino acids in length. They are either labeled or unlabeled, depending upon the diagnostic method. Diagnostic methods
25 involving such a reagent are described below.

Upon expression of a DNA molecule of the invention, a polypeptide or polypeptide derivative is produced and purified using known laboratory techniques. As described above, the polypeptide or polypeptide derivative may be produced as a
30 fusion protein containing a fused tail that facilitates purification. The fusion product is used to immunize a small mammal, e.g., a mouse or a rabbit, in order to raise antibodies against the polypeptide or polypeptide derivative (monospecific antibodies). Accordingly, an eighth aspect of the invention

provides a monospecific antibody that binds to a polypeptide or polypeptide derivative of the invention.

By "monospecific antibody" is meant an antibody that is capable of reacting with a unique naturally-occurring
5 *Chlamydia* polypeptide. An antibody of the invention is either polyclonal or monoclonal. Monospecific antibodies may be recombinant, e.g., chimeric (e.g., constituted by a variable region of murine origin associated with a human constant region), humanized (a human immunoglobulin constant backbone
10 together with hypervariable region of animal, e.g., murine, origin), and/or single chain. Both polyclonal and monospecific antibodies may also be in the form of immunoglobulin fragments, e.g., F(ab)'₂ or Fab fragments. The antibodies of the invention are of any isotype, e.g., IgG or IgA, and polyclonal
15 antibodies are of a single isotype or a mixture of isotypes.

Antibodies against the polypeptides, homologs or fragments of the present invention are generated by immunization of a mammal with a composition comprising said polypeptide, homolog or fragment. Such antibodies may be
20 polyclonal or monoclonal. Methods to produce polyclonal or monoclonal antibodies are well known in the art. For a review, see "Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Eds. E. Harlow and D. Lane (1988), and D.E. Yelton et al., 1981. Ann. Rev. Biochem. 50:657-680. For monoclonal
25 antibodies, see Kohler & Milstein (1975) Nature 256:495-497.

The antibodies of the invention, which are raised to a polypeptide or polypeptide derivative of the invention, are produced and identified using standard immunological assays, e.g., Western blot analysis, dot blot assay, or ELISA (see,
30 e.g., Coligan et al., Current Protocols in Immunology (1994) John Wiley & Sons, Inc., New York, NY). The antibodies are used in diagnostic methods to detect the presence of a *Chlamydia* antigen in a sample, such as a biological sample. The antibodies are also used in affinity chromatography for

purifying a polypeptide or polypeptide derivative of the invention. As is discussed further below, such antibodies may be used in prophylactic and therapeutic passive immunization methods.

5 Accordingly, a ninth aspect of the invention provides (i) a reagent for detecting the presence of *Chlamydia* in a biological sample that contains an antibody, polypeptide, or polypeptide derivative of the invention; and (ii) a diagnostic method for detecting the presence of *Chlamydia* in a biological
10 sample, by contacting the biological sample with an antibody, a polypeptide, or a polypeptide derivative of the invention, such that an immune complex is formed, and by detecting such complex to indicate the presence of *Chlamydia* in the sample or the organism from which the sample is derived.

15 Those skilled in the art will readily understand that the immune complex is formed between a component of the sample and the antibody, polypeptide, or polypeptide derivative, whichever is used, and that any unbound material is removed prior to detecting the complex. It is understood that a
20 polypeptide reagent is useful for detecting the presence of anti-*Chlamydia* antibodies in a sample, e.g., a blood sample, while an antibody of the invention is used for screening a sample, such as a gastric extract or biopsy, for the presence of *Chlamydia* polypeptides.

25 For diagnostic applications, the reagent (i.e., the antibody, polypeptide, or polypeptide derivative of the invention) is either in a free state or immobilized on a solid support, such as a tube, a bead, or any other conventional support used in the field. Immobilization is achieved using
30 direct or indirect means. Direct means include passive adsorption (non-covalent binding) or covalent binding between the support and the reagent. By "indirect means" is meant that an anti-reagent compound that interacts with a reagent is first attached to the solid support. For example, if a polypeptide

reagent is used, an antibody that binds to it can serve as an anti-reagent, provided that it binds to an epitope that is not involved in the recognition of antibodies in biological samples. Indirect means may also employ a ligand-receptor system, for example, where a molecule such as a vitamin is grafted onto the polypeptide reagent and the corresponding receptor immobilized on the solid phase. This is illustrated by the biotin-streptavidin system. Alternatively, a peptide tail is added chemically or by genetic engineering to the reagent and the grafted or fused product immobilized by passive adsorption or covalent linkage of the peptide tail.

Such diagnostic agents may be included in a kit which also comprises instructions for use. The reagent is labeled with a detection means which allows for the detection of the reagent when it is bound to its target. The detection means may be a fluorescent agent such as fluorescein isocyanate or fluorescein isothiocyanate, or an enzyme such as horse radish peroxidase or luciferase or alkaline phosphatase, or a radioactive element such as ^{125}I or ^{51}Cr .

Accordingly, a tenth aspect of the invention provides a process for purifying, from a biological sample, a polypeptide or polypeptide derivative of the invention, which involves carrying out antibody-based affinity chromatography with the biological sample, wherein the antibody is a monospecific antibody of the invention.

For use in a purification process of the invention, the antibody is either polyclonal or monospecific, and preferably is of the IgG type. Purified IgGs is prepared from an antiserum using standard methods (see, e.g., Coligan et al., Current Protocols in Immunology (1994) John Wiley & Sons, Inc., New York, NY.). Conventional chromatography supports, as well as standard methods for grafting antibodies, are described in, e.g., Antibodies: A Laboratory Manual, D. Lane, E. Harlow, Eds. (1988) and outlined below.

Briefly, a biological sample, such as an *C. pneumoniae* extract preferably in a buffer solution, is applied to a chromatography material, preferably equilibrated with the buffer used to dilute the biological sample so that the polypeptide or polypeptide derivative of the invention (i.e., the antigen) is allowed to adsorb onto the material. The chromatography material, such as a gel or a resin coupled to an antibody of the invention, is in either a batch form or a column. The unbound components are washed off and the antigen is then eluted with an appropriate elution buffer, such as a glycine buffer or a buffer containing a chaotropic agent, e.g., guanidine HCl, or high salt concentration (e.g., 3 M MgCl₂). Eluted fractions are recovered and the presence of the antigen is detected, e.g., by measuring the absorbance at 280 nm.

An eleventh aspect of the invention provides (i) a composition of matter comprising a monospecific antibody of the invention, together with a diluent or carrier; (ii) a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a monospecific antibody of the invention, and (iii) a method for treating or preventing a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae* or *C. pecorum*) infection, by administering a therapeutic or prophylactic amount of a monospecific antibody of the invention to an infected individual. Additionally, the eleventh aspect of the invention encompasses the use of a monospecific antibody of the invention in the preparation of a medicament for treating or preventing *Chlamydia* infection.

The monospecific antibody is either polyclonal or monoclonal, preferably of the IgA isotype (predominantly). In passive immunization, the antibody is administered to a mucosal surface of a mammal, e.g., the gastric mucosa, e.g., orally or intragastrically, advantageously, in the presence of a bicarbonate buffer. Alternatively, systemic administration, not requiring a bicarbonate buffer, is carried out. A

monospecific antibody of the invention is administered as a single active component or as a mixture with at least one monospecific antibody specific for a different *Chlamydia* polypeptide. The amount of antibody and the particular regimen used are readily determined by one skilled in the art. For example, daily administration of about 100 to 1,000 mg of antibodies over one week, or three doses per day of about 100 to 1,000 mg of antibodies over two or three days, are effective regimens for most purposes.

Therapeutic or prophylactic efficacy are evaluated using standard methods in the art, e.g., by measuring induction of a mucosal immune response or induction of protective and/or therapeutic immunity, using, e.g., the *C. pneumoniae* mouse model. Those skilled in the art will readily recognize that the *C. pneumoniae* strain of the model may be replaced with another *Chlamydia* strain. For example, the efficacy of DNA molecules and polypeptides from *C. pneumoniae* is preferably evaluated in a mouse model using *C. pneumoniae* strain. Protection is determined by comparing the degree of *Chlamydia* infection to that of a control group. Protection is shown when infection is reduced by comparison to the control group. Such an evaluation is made for polynucleotides, vaccine vectors, polypeptides and derivatives thereof, as well as antibodies of the invention.

Adjuvants useful in any of the vaccine compositions described above are as follows.

Adjuvants for parenteral administration include aluminum compounds, such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate. The antigen is precipitated with, or adsorbed onto, the aluminum compound according to standard protocols. Other adjuvants, such as RIBI (ImmunoChem, Hamilton, MT), are used in parenteral administration.

Adjuvants for mucosal administration include bacterial toxins, e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin A and the *pertussis* toxin (PT), or combinations, subunits, toxoids, or mutants thereof such as a purified preparation of native cholera toxin subunit B (CTB). Fragments, homologs, derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants are described, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/06627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant). Additional LT mutants that are used in the methods and compositions of the invention include, e.g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as a bacterial monophosphoryl lipid A (MPLA) of, e.g., *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella flexneri*; saponins, or polylactide glycolide (PLGA) microspheres, is also be used in mucosal administration.

Adjuvants useful for both mucosal and parenteral administrations include polyphosphazene (WO 95/02415), DC-chol (3 b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol; U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (WO 88/09336).

Any pharmaceutical composition of the invention containing a polynucleotide, a polypeptide, a polypeptide derivative, or an antibody of the invention, is manufactured in a conventional manner. In particular, it is formulated with a pharmaceutically acceptable diluent or carrier, e.g., water or a saline solution such as phosphate buffer saline. In general, a diluent or carrier is selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers or diluents, as well as pharmaceutical necessities for their use in pharmaceutical

formulations, are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field and in the USP/NF.

The invention also includes methods in which

5 *Chlamydia* infection are treated by oral administration of a *Chlamydia* polypeptide of the invention and a mucosal adjuvant, in combination with an antibiotic, an antacid, sucralfate, or a combination thereof. Examples of such compounds that can be administered with the vaccine antigen and the adjuvant are

10 antibiotics, including, e.g., macrolides, tetracyclines, and derivatives thereof (specific examples of antibiotics that can be used include azithromycin or doxycyclin or immunomodulators such as cytokines or steroids). In addition, compounds containing more than one of the above-listed components coupled

15 together, are used. The invention also includes compositions for carrying out these methods, i.e., compositions containing a *Chlamydia* antigen (or antigens) of the invention, an adjuvant, and one or more of the above-listed compounds, in a pharmaceutically acceptable carrier or diluent.

20 It has recently been shown that the 60kDa cysteine rich membrane protein contains a sequence cross-reactive with the murine alpha-myosin heavy chain epitope M7A-alpha, an epitope conserved in humans (Bachmaier et al., Science (1999) 283:1335). This cross-reactivity is proposed to contribute to

25 the development of cardiovascular disease, so it may be beneficial to remove this epitope, and any other epitopes cross-reactive with human antigens, from the protein if it is to be used as a vaccine. Accordingly, a further embodiment of the present invention includes the modification of the coding

30 sequence, for example, by deletion or substitution of the nucleotides encoding the epitope from polynucleotides encoding the protein, as to improve the efficacy and safety of the protein as a vaccine. A similar approach may be appropriate

for any protective antigen found to have unwanted homologies or cross-reactivities with human antigens.

Amounts of the above-listed compounds used in the methods and compositions of the invention are readily determined by one skilled in the art. Treatment/immunization schedules are also known and readily designed by one skilled in the art. For example, the non-vaccine components can be administered on days 1-14, and the vaccine antigen + adjuvant can be administered on days 7, 14, 21, and 28.

10 EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Example 1:

This example illustrates the preparation of a plasmid vector pCAI236 containing the orfF gene.

The orfF gene was amplified from *Chlamydia pneumoniae* genomic DNA by polymerase chain reaction (PCR) using a 5' primer (5' ATAAGAATGCGGCCGCCACCATGTCTTTCTTAAGGCGTCATA 3') (SEQ ID No:3) and a 3' primer (5' GCGCCGGTACCGAATATAAAAAGTTTCTTTATTGGGG 3') (SEQ ID No:4). The 5' primer contains a Not I restriction site, a ribosome binding site, an initiation codon and a sequence at the 5' end of the orfF coding sequence. The 3' primer includes the sequence encoding the C-terminal sequence of the orfF and a Kpn I restriction site. The stop codon was excluded and an additional

nucleotide was inserted to obtain an in-frame fusion with the Histidine tag.

After amplification, the PCR fragment was purified using QIAquick™ PCR purification kit (Qiagen) and then digested with Not I and Kpn I and cloned into the pCA-Myc-His eukaryotic expression vector described in Example 2 (Fig. 3) with transcription under control of the human CMV promoter.

Example 2:

This example illustrates the preparation of the eukaryotic expression vector pCA/Myc-His.

Plasmid pcDNA3.1(-)Myc-His C (Invitrogen) was restricted with Spe I and Bam HI to remove the CMV promoter and the remaining vector fragment was isolated. The CMV promoter and intron A from plasmid VR-1012 (Vical) was isolated on a Spe I / Bam HI fragment. The fragments were ligated together to produce plasmid pCA/Myc-His. The Not I/Kpn I restricted PCR fragment containing the orfF gene was ligated into the Not I and Kpn I restricted plasmid pCA/Myc-His to produce plasmid pCAI236 (Fig 3).

The resulting plasmid, pCAI236, was transferred by electroporation into *E. coli* XL-1 blue (Stratagene) which was grown in LB broth containing 50 µg/ml of carbenicillin. The plasmid was isolated by Endo Free Plasmid Giga Kit™ (Qiagen) large scale DNA purification system. DNA concentration was determined by absorbance at 260 nm and the plasmid was verified after gel electrophoresis and Ethidium bromide staining and comparison to molecular weight standards. The 5' and 3' ends of the gene were verified by sequencing using a LiCor model 4000 L DNA sequencer and IRD-800 labelled primers.

Example 3:

This example illustrates the immunization of mice to achieve protection against an intranasal challenge of *C. pneumoniae*.

It has been previously demonstrated (Yang et. al., 1993) that mice are susceptible to intranasal infection with different isolates of *C. pneumoniae*. Strain AR-39 (Grayston, 1989) was used in Balb/c mice as a challenge infection model to
5 examine the capacity of *Chlamydia* gene products delivered as naked DNA to elicit a protective response against a sublethal *C. pneumoniae* lung infection. Protective immunity is defined as an accelerated clearance of pulmonary infection.

Groups of 7 to 9 week old male Balb/c mice (8 to 10
10 per group) were immunized intramuscularly (i.m.) plus intranasally (i.n.) with plasmid DNA containing the coding sequence of *C.pneumoniae* orfF as described in Examples 1 and 2. Saline or the plasmid vector lacking an inserted Chlamydial gene was given to groups of control animals.

15 For i.m. immunization alternate left and right quadriceps were injected with 100µg of DNA in 50µl of PBS on three occasions at 0, 3 and 6 weeks. For i.n. immunization, anaesthetized mice aspirated 50µl of PBS containing 50 µg DNA on three occasions at 0, 3 and 6 weeks. At week 8, immunized
20 mice were inoculated i.n. with 5×10^5 IFU of *C. pneumoniae*, strain AR39 in 100µl of SPG buffer to test their ability to limit the growth of a sublethal *C. pneumoniae* challenge.

Lungs were taken from mice at day 9 post-challenge and immediately homogenised in SPG buffer (7.5% sucrose, 5mM
25 glutamate, 12.5mM phosphate pH7.5). The homogenate was stored frozen at -70°C until assay. Dilutions of the homogenate were assayed for the presence of infectious *Chlamydia* by inoculation onto monolayers of susceptible cells. The inoculum was centrifuged onto the cells at 3000rpm for 1 hour, then the
30 cells were incubated for three days at 35°C in the presence of 1µg/ml cycloheximide. After incubation the monolayers were fixed with formalin and methanol then immunoperoxidase stained for the presence of Chlamydial inclusions using convalescent

sera from rabbits infected with *C. pneumoniae* and metal-enhanced DAB as a peroxidase substrate.

Figure 4 and Table 1 show that mice immunized i.n. and i.m. with pCAI236 had Chlamydial lung titers less than 24,100 in 6 of 6 cases at day 9 whereas the range of values for control mice sham immunized with saline was 3800-106,100 IFU/lung (mean 49,069) at day 9 in 21 out of 23 cases. DNA immunisation *per se* was not responsible for the observed protective effect since two other plasmid DNA constructs, pCAI116 and pCAI178, failed to protect, with lung titers in immunised mice similar to those obtained for saline-immunized control mice with means of 33583 and 47016 respectively. The constructs pCAI116 and pCAI178 are identical to pCAI236 except that the nucleotide sequence encoding the orfF is replaced with a *C.pneumoniae* nucleotide sequence encoding an unprotective sequence and the nucleoside 5'-diphosphate phosphotransferase protein.

Table 1

MOUSE	BACTERIAL LOAD (INCLUSION FORMING UNITS PER LUNG) IN THE LUNGS OF BALB/C MICE IMMUNIZED WITH VARIOUS DNA IMMUNIZATION CONSTRUCTS			
	IMMUNIZING CONSTRUCT			
	Saline	pCAI116	pCAI178	pCAI236
	Day 9	Day 9	Day 9	Day 9
1	1700	47700	80600	3100
2	36200	12600	31900	21300
3	106100	28600	30600	14600
4	33500	17700	6500	21900
5	70400	77300	53000	7500
6	48700	17600	79500	24000
7	600			
8	19800			
9	29500			
10	100000			
11	15000			
12	56600			
13	60300			
14	88800			
15	30400			
16	69300			
17	47500			
18	96500			
19	30200			
20	84800			
21	3800			
22	65900			
23	33000			
MEAN	49069.57	33583.33	47016.67	15400
SD	32120.48	24832.67	29524.32	8548.22

CLAIMS:

1. A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of:

5 (a) SEQ ID No: 2;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

10 (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

15 2. A nucleic acid molecule comprising a nucleic acid sequence selected from any of:

(a) SEQ ID No: 1;

(b) a sequence which encodes a polypeptide encoded by SEQ ID No: 1;

20 (c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and

(d) a sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to the polypeptides encoded by SEQ ID No: 1.

25 3. A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of claim 1.

4. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to claim 1 and an additional polypeptide.

30

5. The nucleic acid molecule of claim 4 wherein the additional polypeptide is a heterologous signal peptide.

6. The nucleic acid molecule of claim 4 wherein the additional polypeptide has adjuvant activity.

5 7. A nucleic acid molecule according to any one of claims 1 to 6, operatively linked to one or more expression control sequences.

8. A vaccine comprising at least one first nucleic acid according to any one of claims 1, 2, and 4 to 7 and a vaccine
10 vector wherein each first nucleic acid is expressed as a polypeptide, the vaccine optionally comprising a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by said first nucleic acid.

15 9. The vaccine of claim 8 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.

10. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

20 11. A pharmaceutical composition comprising a vaccine according to claim 8 or 9 and a pharmaceutically acceptable carrier.

12. A unicellular host transformed with the nucleic acid molecule of claim 7.

25 13. A nucleic acid probe of 5 to 100 nucleotides which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID No: 1, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

14. A primer of 10 to 40 nucleotides which hybridizes under stringent conditions to the nucleic acid molecules of SEQ ID No: 1, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

5 15. A polypeptide encoded by a nucleic acid sequence according to any one of claims 1, 2 and 4 to 7.

16. A polypeptide comprising an amino acid sequence selected from any of:

- (a) SEQ ID No: 2;
- 10 (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and
- (c) a polypeptide of (a) or (b) which has been modified to improve its immunogenicity, wherein said modified
15 polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

17. A fusion polypeptide comprising a polypeptide of claim 15 or 16 and an additional polypeptide.

20 18. The fusion polypeptide of claim 17 wherein the additional polypeptide is a heterologous signal peptide.

19. The fusion protein of claim 17 wherein the additional polypeptide has adjuvant activity.

20. A method for producing a polypeptide of claim 15 or
25 16, comprising the step of culturing a unicellular host according to claim 12.

21. An antibody against the polypeptide of any one of claims 15 to 19.

22. A vaccine comprising at least one first polypeptide according to any one of claims 15 to 19 and a pharmaceutically acceptable carrier, optionally comprising a second polypeptide which enhances the immune response to the first polypeptide.

5 23. The vaccine of claim 22 wherein the second polypeptide comprises an additional *Chlamydia* polypeptide.

24. A pharmaceutical composition comprising a polypeptide according to any one of claims 15 to 19 and a pharmaceutically acceptable carrier.

10 25. A pharmaceutical composition comprising a vaccine according to claim 22 or 23 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising an antibody according to claim 21 and a pharmaceutically acceptable
15 carrier.

27. A method for preventing or treating *Chlamydia* infection using:

- (a) the nucleic acid of any one of claims 1 to 7;
- (b) the vaccine of any one of claims 8, 9, 22 and 23;
- 20 (c) the pharmaceutical composition of any one of claims 10, 11, 24 to 26;
- (d) the polypeptide of any one of claims 15 to 19; or
- (e) the antibody of claim 21.

28. A method of detecting *Chlamydia* infection comprising
25 the step of assaying a body fluid of a mammal to be tested, with a component selected from any one of:

- (a) the nucleic acid of any one of claims 1 to 7;
- (b) the polypeptide of any one of claims 15 to 19; and
- (c) the antibody of claim 21.

29. A diagnostic kit comprising instructions for use and a component selected from any one of:

- (a) the nucleic acid of any one of claims 1 to 7;
- (b) the polypeptide of any one of claims 15 to 19; and
- (c) the antibody of claim 21.

30. A method for identifying a polypeptide of claims 15 to 19 which induces an immune response effective to prevent or lessen the severity of *Chlamydia* infection in a mammal previously immunized with polypeptide, comprising the steps of:

- (a) immunizing a mouse with the polypeptide; and
- (b) inoculating the immunized mouse with *Chlamydia*;

wherein the polypeptide which prevents or lessens the severity of *Chlamydia* infection in the immunized mouse compared to a non-immunized control mouse is identified.

31. Expression plasmid pCAI236.

32. A nucleic acid molecule of SEQ ID NO. 3 or 4.

33. An orfF polypeptide from *Chlamydia*.

34. An orfF polypeptide from *Chlamydia pneumoniae*.


ctagcgctct	tcgtcacatt	gataagctcg			gattagagaa			agttctcgaa			agagctaaaa			60													
gtaaaaaat															ttatttaac	ttaagtata			ggaaatat			atg	tct	ttc	tta	agg	115
																			Met	Ser	Phe	Leu	Arg	5			
cgt	cat	att	tct	ctt	ttt	cgt	tca	caa	aaa	caa	ctt	att	gat	gtt	ttt	163											
Arg	His	Ile	Ser	Leu	Phe	Arg	Ser	Gln	Lys	Gln	Leu	Ile	Asp	Val	Phe	20											
				10			15																				
gct	ccc	gta	agt	cct	aac	ctc	gag	tta	gct	gag	att	cat	cgt	cgt	gtt	211											
Ala	Pro	Val	Ser	Pro	Asn	Leu	Glu	Leu	Ala	Glu	Ile	His	Arg	Arg	Val	35											
			25			30																					
att	gaa	gat	caa	ggc	cct	gcc	ctt	ctt	ttt	cat	aat	gtc	atc	gga	tcg	259											
Ile	Glu	Asp	Gln	Gly	Pro	Ala	Leu	Leu	Phe	His	Asn	Val	Ile	Gly	Ser	50											
		40			45																						
tca	ttc	cca	gtc	ctg	acc	aat	ctc	ttt	gga	aca	aaa	cat	cgt	gta	gac	307											
Ser	Phe	Pro	Val	Leu	Thr	Asn	Leu	Phe	Gly	Thr	Lys	His	Arg	Val	Asp	65											
		55			60																						
caa	ctt	ttt	tct	caa	gct	cct	gat	aac	ctc	atc	gct	cga	gtt	gcc	cac	355											
Gln	Leu	Phe	Ser	Gln	Ala	Pro	Asp	Asn	Leu	Ile	Ala	Arg	Val	Ala	His	85											
70			75			80																					
ctt	att	tct	tct	aca	cca	aag	ctt	tct	tct	cta	tgg	aaa	tct	cgg	gat	403											
Leu	Ile	Ser	Ser	Thr	Pro	Lys	Leu	Ser	Ser	Leu	Trp	Lys	Ser	Arg	Asp	100											
				90			95																				
cta	tta	aaa	aga	ata	agc	tct	tta	ggg	ctc	aaa	aaa	gct	cga	ttc	cgt	451											
Leu	Leu	Lys	Arg	Ile	Ser	Ser	Leu	Gly	Leu	Lys	Lys	Ala	Arg	Phe	Arg	115											
			105			110																					
cgc	ttt	cct	ttt	gtt	tct	atg	tcc	tca	gtt	aac	tta	gat	cac	ctt	ccc	499											
Arg	Phe	Pro	Phe	Val	Ser	Met	Ser	Ser	Val	Asn	Leu	Asp	His	Leu	Pro	130											
		120			125																						
tta	ctc	aca	agc	tgg	cct	gaa	gat	ggg	gga	gcc	ttt	ctc	aca	ctt	cct	547											
Leu	Leu	Thr	Ser	Trp	Pro	Glu	Asp	Gly	Gly	Ala	Phe	Leu	Thr	Leu	Pro	145											
		135			140																						
ctt	gtc	tat	acg	gaa	tcg	ccg	act	ctt	act	aca	ccc	aat	ctt	ggg	atg	595											
Leu	Val	Tyr	Thr	Glu	Ser	Pro	Thr	Leu	Thr	Thr	Pro	Asn	Leu	Gly	Met	165											
150			155			160																					
tat	cgc	gtg	caa	cgg	ttc	aat	caa	aac	acc	atg	ggc	ctc	cat	ttt	caa	643											
Tyr	Arg	Val	Gln	Arg	Phe	Asn	Gln	Asn	Thr	Met	Gly	Leu	His	Phe	Gln	180											
				170			175																				

2/12


atc cag aag ggc gga ggg atg cat ctg tat gaa gca gag caa aaa aag	691
Ile Gln Lys Gly Gly Gly Met His Leu Tyr Glu Ala Glu Gln Lys Lys	
185 190 195	
caa aac ctt cct gtt tcg gta ttt ttg tct gga aac ccc ttt tta acc	739
Gln Asn Leu Pro Val Ser Val Phe Leu Ser Gly Asn Pro Phe Leu Thr	
200 205 210	
ctt tct gcg att gcc ccc cta cct gag aat gtc tcg gaa ctt ctc ttt	787
Leu Ser Ala Ile Ala Pro Leu Pro Glu Asn Val Ser Glu Leu Leu Phe	
215 220 225	
gct acc ttc ctc caa gga gcg aag ctc ctt tat aaa aaa aca aac gac	835
Ala Thr Phe Leu Gln Gly Ala Lys Leu Leu Tyr Lys Lys Thr Asn Asp	
230 235 240 245	
cat ccc cac cct cta ctc tac gat gcg gaa ttc atc ctg gtc gga gaa	883
His Pro His Pro Leu Leu Tyr Asp Ala Glu Phe Ile Leu Val Gly Glu	
250 255 260	
tct ccg gcc ggg aaa cgt cgt cct gaa ggt cct ttt ggc gat cat ttc	931
Ser Pro Ala Gly Lys Arg Arg Pro Glu Gly Pro Phe Gly Asp His Phe	
265 270 275	
gga tac tac agt ctc caa cat gac ttc cct gaa ttc cac tgt cat aaa	979
Gly Tyr Tyr Ser Leu Gln His Asp Phe Pro Glu Phe His Cys His Lys	
280 285 290	
atc tat cac aga aaa gat gca atc tat cct gct aca gta gtc ggc aaa	1027
Ile Tyr His Arg Lys Asp Ala Ile Tyr Pro Ala Thr Val Val Gly Lys	
295 300 305	
ccc tac caa gaa gat ttt tat ata ggg aac aaa ctc caa gaa tac ctc	1075
Pro Tyr Gln Glu Asp Phe Tyr Ile Gly Asn Lys Leu Gln Glu Tyr Leu	
310 315 320 325	
tcc cct tta ttt ccg tta gtt atg cct ggt gtg cgt aga ctt aaa agt	1123
Ser Pro Leu Phe Pro Leu Val Met Pro Gly Val Arg Arg Leu Lys Ser	
330 335 340	
tac gga gaa tca ggg ttt cat gca ctg act gcg gct gtc gtt aaa gaa	1171
Tyr Gly Glu Ser Gly Phe His Ala Leu Thr Ala Ala Val Val Lys Glu	
345 350 355	
cgc tat tgg aga gaa tct cta acc aca gct ctt aga att ctt gga gag	1219
Arg Tyr Trp Arg Glu Ser Leu Thr Thr Ala Leu Arg Ile Leu Gly Glu	
360 365 370	
ggc caa ctt tcc cta acg aaa ttc cta atg gtc aca gac caa gag gtg	1267
Gly Gln Leu Ser Leu Thr Lys Phe Leu Met Val Thr Asp Gln Glu Val	
375 380 385	
cct ctc gac agg ttc tcc gtg gtt cta gaa acc att tta gag cgt cta	1315
Pro Leu Asp Arg Phe Ser Val Val Leu Glu Thr Ile Leu Glu Arg Leu	
390 395 400 405	

3/12


cag cca gac cga gat ctt att att ttc tca gaa act gca aac gat acg	1363
Gln Pro Asp Arg Asp Leu Ile Ile Phe Ser Glu Thr Ala Asn Asp Thr	
410 415 420	
tta gac tat aca gga cca agc tta aat aag ggc tcc aag gga atc ttc	1411
Leu Asp Tyr Thr Gly Pro Ser Leu Asn Lys Gly Ser Lys Gly Ile Phe	
425 430 435	
atg gga ata gga aaa gcc atc cga gac ctt ccc cat gga tat cag gga	1459
Met Gly Ile Gly Lys Ala Ile Arg Asp Leu Pro His Gly Tyr Gln Gly	
440 445 450	
gga aaa atc cat gga gtt caa gac atc gct ccc ttt tgt cgt ggt tgc	1507
Gly Lys Ile His Gly Val Gln Asp Ile Ala Pro Phe Cys Arg Gly Cys	
455 460 465	
cta gtg ttg gaa aca tcc ctc gag gac cga tgt att aaa tct ctc ctt	1555
Leu Val Leu Glu Thr Ser Leu Glu Asp Arg Cys Ile Lys Ser Leu Leu	
470 475 480 485	
cac cat cca gat cta aaa tca tgg cct ctg att atc ctt gcc gat aat	1603
His His Pro Asp Leu Lys Ser Trp Pro Leu Ile Ile Leu Ala Asp Asn	
490 495 500	
ctg aga gaa acc att caa agt gaa aaa gat ttt ctc tgg agg acc ttc	1651
Leu Arg Glu Thr Ile Gln Ser Glu Lys Asp Phe Leu Trp Arg Thr Phe	
505 510 515	
aca cga tgt gcc cca gca aat gat ctt cac gcg ctc cac agc cat ttt	1699
Thr Arg Cys Ala Pro Ala Asn Asp Leu His Ala Leu His Ser His Phe	
520 525 530	
gct act cac cgt cct aat tac aac ttt ccc ttc gtt atc gat gcc ctg	1747
Ala Thr His Arg Pro Asn Tyr Asn Phe Pro Phe Val Ile Asp Ala Leu	
535 540 545	
atg aag cct tcc tat cct aaa gaa gta gag gtc gac cca tct aca aaa	1795
Met Lys Pro Ser Tyr Pro Lys Glu Val Glu Val Asp Pro Ser Thr Lys	
550 555 560 565	
caa aag gtt tcc gaa cga tgg cac gca tat ttc ccc aat aaa gaa act	1843
Gln Lys Val Ser Glu Arg Trp His Ala Tyr Phe Pro Asn Lys Glu Thr	
570 575 580	
ttt tat att taataagaat cttattctat taaacgttta attaaattag	1892
Phe Tyr Ile	
ttattttatt tttaaaaata tataaaaaca aaaaagctat tttaagagta aaaaatgaat	1952
aaa	1955

Figure 2: Restriction enzyme analysis of the *C. pneumoniae* orfF gene

5/12



6/12



7/12

AvaII Hpy188IX
 EcoO109I Eco57I
 Psp5II BciVI
 Sau96I BaeI
 Sse8647I DpnI
 Hpy178III Sau3AI TaaI NlaIII BaeI
 SfcI BsmAI
 TCGTCCTGAAGGTCCTTTTGGCGATCATTTCGGATACTACAGTCTCCAACATGACTTCCC
 901 -----+-----+-----+-----+-----+ 960
 AGCAGGACTTCCAGGAAAACCGCTAGTAAAGCCTATGATGTCAGAGGTTGTACTGAAGGG

ApoI TspRI
 EcoRI TaaI
 Tsp509I MmeI SfaNI CviRI SfcI TaaI
 TGAATTCCACTGTCATAAAATCTATCACAGAAAAGATGCAATCTATCCTGCTACAGTAGT
 961 -----+-----+-----+-----+-----+ 1020
 ACTTAAGGTGACAGTATTTTAGATAGTGTCTTTCTACGTTAGATAGGACGATGTCATCA

MboII
 CGGCAAACCTACCAAGAAGATTTTATATAGGGAACAACTCCAAGAATACCTCTCCCC
 1021 -----+-----+-----+-----+-----+ 1080
 GCCGTTTGGGATGGTTCTTCTAAAAATATATCCCTTGTTTGAGGTTCTTATGGAGAGGGG

ScrFI MaeIII HinfI
 MnlI EcoRII MwoI AccI MseI TfiI
 TTTATTTCCGTTAGTTATGCCTGGTGTGCGTAGACTTAAAAGTTACGGAGAATCAGGGTT
 1081 -----+-----+-----+-----+-----+ 1140
 AAATAAAGGCAATCAATACGGACCACACGCATCTGAATTTTCAATGCCTCTTAGTCCCAA

CjePI
 CviJI
 Fnu4HI
 TauI
 AciI
 TspRI
 BstAPI Hin4I
 CviRI HinfI AluI
 NlaIII MwoI MseI TfiI CjePI CviJI
 TCATGCACTGACTGCGGCTGTCGTTAAAGAACGCTATTGGAGAGAATCTCTAACCACAGC
 1141 -----+-----+-----+-----+-----+ 1200
 AGTACGTGACTGACGCCGACAGCAATTTCTTGCGATAACCTCTCTTAGAGATTGGTGTCTG

MnlI
 AceIII
 ApoI
 EcoRI
 Tsp509I CviJI
 BplI HaeIII
 DdeI Sau96I ApoI MaeIII
 Tsp509I Tsp45I MnlI
 TCTTAGAATTCTTGAGAGGGCCAACTTTCCCTAACGAAATTCCTAATGGTTCACAGACCA
 1201 -----+-----+-----+-----+-----+ 1260
 AGAATCTTAAGAACCTCTCCCGGTTGAAAGGGATTGCTTTAAGGATTACCAGTGTCTGGT

Hpy178III
 BsaJI
 Hpy178III
 BstDSI
 Hpy178III
 BsaXI
 BfaI
 NgoGV
 NlaIV
 BanI
 TaqI
 MnlI
 DrdII
 HgaI
 CviJI
 MwoI
 SfcI
 AccI
 AGAGGTGCCTCTCGACAGGTTCTCCGTGGTTCTAGAAACCATTTTAGAGCGTCTACAGCC
 1261 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1320
 TCTCCACGGAGAGCTGTCCAAGAGGCACCAAGATCTTTGGTAAATCTCGCAGATGTCGG

DpnI
 BglII
 BstYI
 Sau3AI
 Hpy188IX
 DdeI
 CviRI
 AlwNI
 MaeII
 BseMII
 AvaII
 Sau96I
 AGACCGAGATCTTATTATTTTCTCAGAACTGCAAACGATACGTTAGACTATACAGGACC
 1321 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1380
 TCTGGCTCTAGAATAATAAAAGAGTCTTTGACGTTTGCTATGCAATCTGATATGTCCTGG

MboII
 BsaJI
 StyI
 BanII
 Bsp1286I
 MseI
 AluI
 CviJI
 HindIII
 NgoGV
 NlaIV
 CjePI
 CviJI
 HinfI
 TfiI
 FokI
 NlaIII
 Hpy188IX
 BccI
 BsaI
 BsmAI
 CjePI
 CviJI
 AAGCTTAAATAAGGGCTCCAAGGGAATCTTCATGGGAATAGGAAAAGCCATCCGAGACCT
 1381 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1440
 TTCGAATTTATTCCCGAGGTTCCCTTAGAAGTACCCTTATCCTTTTCGGTAGGCTCTGGA

EcoRV
 MnlI
 NlaIII
 BsaJI
 BstDSI
 NcoI
 StyI
 Hpy178III
 NlaIII
 BsaJI
 BstDSI
 NcoI
 StyI
 Hin4I
 MmeI
 TCCCCATGGATATCAGGGAGGAAAAATCCATGGAGTTCAAGACATCGCTCCCTTTTGTCTG
 1441 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1500
 AGGGGTACCTATAGTCCCTCCTTTTTAGGTACCTCAAGTTCTGTAGCGAGGGAAAACAGC

AvaII
 Sau96I
 TaqI
 AvaI
 SmlI
 XhoI
 BfaI
 BsbI
 FokI
 BslI
 MnlI
 MnlI
 MseI
 BccI
 TaqII
 HphI
 FokI
 TGGTTGCCTAGTGTTGGAAACATCCCTCGAGGACCGATGTATTAAATCTCTCCTTCACCA
 1501 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1560
 ACCAACGGATCACAACCTTTGTAGGGAGCTCCTGGCTACATAATTTAGAGAGGAAGTGGT

9/12

```

      HaeIV
      Hin4I
      DpnI
      BglII
      BstYI
      Sau3AI
      Hpy178III
      Hpy188IX
      CviJI
      HaeI
      HaeIII
      NlaIII
      BseMII
      MnlI
      CjeI
      DdeI
      Hpy188IX
      XmnI
TCCAGATCTAAAATCATGGCCTCTGATTATCCTTGCCGATAATCTGAGAGAAACCATTCA
1561 -----+-----+-----+-----+-----+-----+-----+ 1620
AGGTCTAGATTTTAGTACCGGAGACTAATAGGAACGGCTATTAGACTCTCTTTGGTAAGT

      AvaII
      EcoO109I
      Psp5II
      Sau96I
      Sse8647I
      Hpy178III
      CjeI
      CjePI
      MnlI
      DraIII
      CjePI
      Bsp1286I
      BmgI
      BseSI
      BpmI
      MboII
      Sau3AI
      DpnI
AAGTGAAAAAGATTTTCTCTGGAGGACCTTCACACGATGTGCCCCAGCAAATGATCTTCA
1621 -----+-----+-----+-----+-----+-----+-----+ 1680
TTCACTTTTTCTAAAAGAGACCTCCTGGAAGTGTGCTACACGGGGTCGTTTACTAGAAGT

      HhaI
      ThaI
      CviJI
      HphI
      Tsp509I
      TaaI
      SfaNI
      ClaI
      TaqI
CGCGCTCCACAGCCATTTTGCTACTCACCGTCCTAATTACAACCTTCCCTTCGTTATCGA
1681 -----+-----+-----+-----+-----+-----+-----+ 1740
GCGCGAGGTGTCTGTAACGATGAGTGGCAGGATTAATGTTGAAAGGGAAGCAATAGCT

      HincII
      SimI
      AccI
      TaqI
      CviJI
      MnlI
      SalI
      BccI
TGCCCTGATGAAGCCTTCCTATCCTAAAGAAGTAGAGGTCGACCCATCTACAAAACAAAA
1741 -----+-----+-----+-----+-----+-----+-----+ 1800
ACGGGACTACTTCGGAAGGATAGGATTTCTTCATCTCCAGCTGGGTAGATGTTTTGTTTT

      Cac8I
      BccI
      Hpy188IX
      BslI
      HinfI
      MseI
      TfiI
GGTTTCCGAACGATGGCAGCATATTTCCCAATAAAAGAACTTTTTATATTTAATAAGA
1801 -----+-----+-----+-----+-----+-----+-----+ 1860
CCAAAGGCTTGCTACCGTGCGTATAAAGGGTTATTTCTTTGAAAAATATAAATTATTCT

```

10/12

```

                                Tsp509I
                                MseI
                                PacI
                                Tsp509I
                                AclI
                                MaeII
                                MseI   MseI
                                |       |
ATCTTATTCTATTAAACGTTTAATTAAATTAGTTATTTTATTTTAAAAATATATAAAAA
1861 -----+-----+-----+-----+-----+-----+ 1920
TAGAATAAGATAATTTGCAAATTAATTTAATCAATAAAATAAAAATTTTATATATTTTT

                                AluI
                                CviJI  MseI
                                |       |
CAAAAAAGCTATTTTAAAGAGTAAAAAATGAATAAA
1921 -----+-----+-----+----- 1955
GTTTTTTCGATAAAATTCTCATTTTTTACTTATTT
```





FIG. 3
Construction of pCAI236

12/12

Figure 4: Protective efficacy of DNA immunization with pCAI236



SEQUENCE LISTING

<110> Aventis Pasteur Limited

<120> Chlamydia antigens and corresponding DNA fragments and uses thereof

<130> 77813-14

<140>

<141>

<150> US 60/141,270

<151> 1999-06-30

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 1955

<212> DNA

<213> Chlamydia pneumoniae

<220>

<221> CDS

<222> (101)..(1852)

<400> 1

```

ctagcgctct tcgtcacatt gataagctcg gattagagaa agttctcgaa agagctaaaa 60
gtaaaaattt ttaatttaac ttaagtatag ggaaatatat atg tct ttc tta agg 115
                                         Met Ser Phe Leu Arg
                                         1           5

cgt cat att tct ctt ttt cgt tca caa aaa caa ctt att gat gtt ttt 163
Arg His Ile Ser Leu Phe Arg Ser Gln Lys Gln Leu Ile Asp Val Phe
              10              15              20

gct ccc gta agt cct aac ctc gag tta gct gag att cat cgt cgt gtt 211
Ala Pro Val Ser Pro Asn Leu Glu Leu Ala Glu Ile His Arg Arg Val
              25              30              35

att gaa gat caa ggc cct gcc ctt ctt ttt cat aat gtc atc gga tcg 259
Ile Glu Asp Gln Gly Pro Ala Leu Leu Phe His Asn Val Ile Gly Ser
              40              45              50

tca ttc cca gtc ctg acc aat ctc ttt gga aca aaa cat cgt gta gac 307
Ser Phe Pro Val Leu Thr Asn Leu Phe Gly Thr Lys His Arg Val Asp
              55              60              65

caa ctt ttt tct caa gct cct gat aac ctc atc gct cga gtt gcc cac 355
Gln Leu Phe Ser Gln Ala Pro Asp Asn Leu Ile Ala Arg Val Ala His
              70              75              80              85

ctt att tct tct aca cca aag ctt tct tct cta tgg aaa tct cgg gat 403
Leu Ile Ser Ser Thr Pro Lys Leu Ser Ser Leu Trp Lys Ser Arg Asp
              90              95              100

cta tta aaa aga ata agc tct tta ggg ctc aaa aaa gct cga ttc cgt 451
Leu Leu Lys Arg Ile Ser Ser Leu Gly Leu Lys Lys Ala Arg Phe Arg
              105              110              115

```

cgc ttt cct ttt gtt tct atg tcc tca gtt aac tta gat cac ctt ccc 499
 Arg Phe Pro Phe Val Ser Met Ser Ser Val Asn Leu Asp His Leu Pro
 120 125 130

tta ctc aca agc tgg cct gaa gat ggt gga gcc ttt ctc aca ctt cct 547
 Leu Leu Thr Ser Trp Pro Glu Asp Gly Gly Ala Phe Leu Thr Leu Pro
 135 140 145

ctt gtc tat acg gaa tcg ccg act ctt act aca ccc aat ctt ggg atg 595
 Leu Val Tyr Thr Glu Ser Pro Thr Leu Thr Thr Pro Asn Leu Gly Met
 150 155 160 165

tat cgc gtg caa cgg ttc aat caa aac acc atg ggc ctc cat ttt caa 643
 Tyr Arg Val Gln Arg Phe Asn Gln Asn Thr Met Gly Leu His Phe Gln
 170 175 180

atc cag aag ggc gga ggg atg cat ctg tat gaa gca gag caa aaa aag 691
 Ile Gln Lys Gly Gly Gly Met His Leu Tyr Glu Ala Glu Gln Lys Lys
 185 190 195

caa aac ctt cct gtt tcg gta ttt ttg tct gga aac ccc ttt tta acc 739
 Gln Asn Leu Pro Val Ser Val Phe Leu Ser Gly Asn Pro Phe Leu Thr
 200 205 210

ctt tct gcg att gcc ccc cta cct gag aat gtc tcg gaa ctt ctc ttt 787
 Leu Ser Ala Ile Ala Pro Leu Pro Glu Asn Val Ser Glu Leu Leu Phe
 215 220 225

gct acc ttc ctc caa gga gcg aag ctc ctt tat aaa aaa aca aac gac 835
 Ala Thr Phe Leu Gln Gly Ala Lys Leu Leu Tyr Lys Lys Thr Asn Asp
 230 235 240 245

cat ccc cac cct cta ctc tac gat gcg gaa ttc atc ctg gtc gga gaa 883
 His Pro His Pro Leu Leu Tyr Asp Ala Glu Phe Ile Leu Val Gly Glu
 250 255 260

tct ccg gcc ggg aaa cgt cgt cct gaa ggt cct ttt ggc gat cat ttc 931
 Ser Pro Ala Gly Lys Arg Arg Pro Glu Gly Pro Phe Gly Asp His Phe
 265 270 275

gga tac tac agt ctc caa cat gac ttc cct gaa ttc cac tgt cat aaa 979
 Gly Tyr Tyr Ser Leu Gln His Asp Phe Pro Glu Phe His Cys His Lys
 280 285 290

atc tat cac aga aaa gat gca atc tat cct gct aca gta gtc ggc aaa 1027
 Ile Tyr His Arg Lys Asp Ala Ile Tyr Pro Ala Thr Val Val Gly Lys
 295 300 305

ccc tac caa gaa gat ttt tat ata ggg aac aaa ctc caa gaa tac ctc 1075
 Pro Tyr Gln Glu Asp Phe Tyr Ile Gly Asn Lys Leu Gln Glu Tyr Leu
 310 315 320 325

tcc cct tta ttt ccg tta gtt atg cct ggt gtg cgt aga ctt aaa agt 1123
 Ser Pro Leu Phe Pro Leu Val Met Pro Gly Val Arg Arg Leu Lys Ser
 330 335 340

tac gga gaa tca ggg ttt cat gca ctg act gcg gct gtc gtt aaa gaa 1171
 Tyr Gly Glu Ser Gly Phe His Ala Leu Thr Ala Ala Val Val Lys Glu
 345 350 355

3/6

cgc tat tgg aga gaa tct cta acc aca gct ctt aga att ctt gga gag 1219
 Arg Tyr Trp Arg Glu Ser Leu Thr Thr Ala Leu Arg Ile Leu Gly Glu
 360 365 370

ggc caa ctt tcc cta acg aaa ttc cta atg gtc aca gac caa gag gtg 1267
 Gly Gln Leu Ser Leu Thr Lys Phe Leu Met Val Thr Asp Gln Glu Val
 375 380 385

cct ctc gac agg ttc tcc gtg gtt cta gaa acc att tta gag cgt cta 1315
 Pro Leu Asp Arg Phe Ser Val Val Leu Glu Thr Ile Leu Glu Arg Leu
 390 395 400 405

cag cca gac cga gat ctt att att ttc tca gaa act gca aac gat acg 1363
 Gln Pro Asp Arg Asp Leu Ile Ile Phe Ser Glu Thr Ala Asn Asp Thr
 410 415 420

tta gac tat aca gga cca agc tta aat aag ggc tcc aag gga atc ttc 1411
 Leu Asp Tyr Thr Gly Pro Ser Leu Asn Lys Gly Ser Lys Gly Ile Phe
 425 430 435

atg gga ata gga aaa gcc atc cga gac ctt ccc cat gga tat cag gga 1459
 Met Gly Ile Gly Lys Ala Ile Arg Asp Leu Pro His Gly Tyr Gln Gly
 440 445 450

gga aaa atc cat gga gtt caa gac atc gct ccc ttt tgt cgt ggt tgc 1507
 Gly Lys Ile His Gly Val Gln Asp Ile Ala Pro Phe Cys Arg Gly Cys
 455 460 465

cta gtg ttg gaa aca tcc ctc gag gac cga tgt att aaa tct ctc ctt 1555
 Leu Val Leu Glu Thr Ser Leu Glu Asp Arg Cys Ile Lys Ser Leu Leu
 470 475 480 485

cac cat cca gat cta aaa tca tgg cct ctg att atc ctt gcc gat aat 1603
 His His Pro Asp Leu Lys Ser Trp Pro Leu Ile Ile Leu Ala Asp Asn
 490 495 500

ctg aga gaa acc att caa agt gaa aaa gat ttt ctc tgg agg acc ttc 1651
 Leu Arg Glu Thr Ile Gln Ser Glu Lys Asp Phe Leu Trp Arg Thr Phe
 505 510 515

aca cga tgt gcc cca gca aat gat ctt cac gcg ctc cac agc cat ttt 1699
 Thr Arg Cys Ala Pro Ala Asn Asp Leu His Ala Leu His Ser His Phe
 520 525 530

gct act cac cgt cct aat tac aac ttt ccc ttc gtt atc gat gcc ctg 1747
 Ala Thr His Arg Pro Asn Tyr Asn Phe Pro Phe Val Ile Asp Ala Leu
 535 540 545

atg aag cct tcc tat cct aaa gaa gta gag gtc gac cca tct aca aaa 1795
 Met Lys Pro Ser Tyr Pro Lys Glu Val Glu Val Asp Pro Ser Thr Lys
 550 555 560 565

caa aag gtt tcc gaa cga tgg cac gca tat ttc ccc aat aaa gaa act 1843
 Gln Lys Val Ser Glu Arg Trp His Ala Tyr Phe Pro Asn Lys Glu Thr
 570 575 580

ttt tat att taataagaat cttattctat taaacgttta attaaattag 1892
 Phe Tyr Ile

ttatttttatt ttttaaaaata tataaaaaca aaaaagctat ttttaagagta aaaaatgaat 1952

aaa

1955

<210> 2

<211> 584

<212> PRT

<213> Chlamydia pneumoniae

<400> 2

Met Ser Phe Leu Arg Arg His Ile Ser Leu Phe Arg Ser Gln Lys Gln
 1 5 10 15

Leu Ile Asp Val Phe Ala Pro Val Ser Pro Asn Leu Glu Leu Ala Glu
 20 25 30

Ile His Arg Arg Val Ile Glu Asp Gln Gly Pro Ala Leu Leu Phe His
 35 40 45

Asn Val Ile Gly Ser Ser Phe Pro Val Leu Thr Asn Leu Phe Gly Thr
 50 55 60

Lys His Arg Val Asp Gln Leu Phe Ser Gln Ala Pro Asp Asn Leu Ile
 65 70 75 80

Ala Arg Val Ala His Leu Ile Ser Ser Thr Pro Lys Leu Ser Ser Leu
 85 90 95

Trp Lys Ser Arg Asp Leu Leu Lys Arg Ile Ser Ser Leu Gly Leu Lys
 100 105 110

Lys Ala Arg Phe Arg Arg Phe Pro Phe Val Ser Met Ser Ser Val Asn
 115 120 125

Leu Asp His Leu Pro Leu Leu Thr Ser Trp Pro Glu Asp Gly Gly Ala
 130 135 140

Phe Leu Thr Leu Pro Leu Val Tyr Thr Glu Ser Pro Thr Leu Thr Thr
 145 150 155 160

Pro Asn Leu Gly Met Tyr Arg Val Gln Arg Phe Asn Gln Asn Thr Met
 165 170 175

Gly Leu His Phe Gln Ile Gln Lys Gly Gly Gly Met His Leu Tyr Glu
 180 185 190

Ala Glu Gln Lys Lys Gln Asn Leu Pro Val Ser Val Phe Leu Ser Gly
 195 200 205

Asn Pro Phe Leu Thr Leu Ser Ala Ile Ala Pro Leu Pro Glu Asn Val
 210 215 220

Ser Glu Leu Leu Phe Ala Thr Phe Leu Gln Gly Ala Lys Leu Leu Tyr
 225 230 235 240

Lys Lys Thr Asn Asp His Pro His Pro Leu Leu Tyr Asp Ala Glu Phe
 245 250 255

Ile Leu Val Gly Glu Ser Pro Ala Gly Lys Arg Arg Pro Glu Gly Pro
 260 265 270

Phe Gly Asp His Phe Gly Tyr Tyr Ser Leu Gln His Asp Phe Pro Glu
 275 280 285
 Phe His Cys His Lys Ile Tyr His Arg Lys Asp Ala Ile Tyr Pro Ala
 290 295 300
 Thr Val Val Gly Lys Pro Tyr Gln Glu Asp Phe Tyr Ile Gly Asn Lys
 305 310 315 320
 Leu Gln Glu Tyr Leu Ser Pro Leu Phe Pro Leu Val Met Pro Gly Val
 325 330 335
 Arg Arg Leu Lys Ser Tyr Gly Glu Ser Gly Phe His Ala Leu Thr Ala
 340 345 350
 Ala Val Val Lys Glu Arg Tyr Trp Arg Glu Ser Leu Thr Thr Ala Leu
 355 360 365
 Arg Ile Leu Gly Glu Gly Gln Leu Ser Leu Thr Lys Phe Leu Met Val
 370 375 380
 Thr Asp Gln Glu Val Pro Leu Asp Arg Phe Ser Val Val Leu Glu Thr
 385 390 395 400
 Ile Leu Glu Arg Leu Gln Pro Asp Arg Asp Leu Ile Ile Phe Ser Glu
 405 410 415
 Thr Ala Asn Asp Thr Leu Asp Tyr Thr Gly Pro Ser Leu Asn Lys Gly
 420 425 430
 Ser Lys Gly Ile Phe Met Gly Ile Gly Lys Ala Ile Arg Asp Leu Pro
 435 440 445
 His Gly Tyr Gln Gly Gly Lys Ile His Gly Val Gln Asp Ile Ala Pro
 450 455 460
 Phe Cys Arg Gly Cys Leu Val Leu Glu Thr Ser Leu Glu Asp Arg Cys
 465 470 475 480
 Ile Lys Ser Leu Leu His His Pro Asp Leu Lys Ser Trp Pro Leu Ile
 485 490 495
 Ile Leu Ala Asp Asn Leu Arg Glu Thr Ile Gln Ser Glu Lys Asp Phe
 500 505 510
 Leu Trp Arg Thr Phe Thr Arg Cys Ala Pro Ala Asn Asp Leu His Ala
 515 520 525
 Leu His Ser His Phe Ala Thr His Arg Pro Asn Tyr Asn Phe Pro Phe
 530 535 540
 Val Ile Asp Ala Leu Met Lys Pro Ser Tyr Pro Lys Glu Val Glu Val
 545 550 555 560
 Asp Pro Ser Thr Lys Gln Lys Val Ser Glu Arg Trp His Ala Tyr Phe
 565 570 575
 Pro Asn Lys Glu Thr Phe Tyr Ile
 580

<210> 3
<211> 42
<212> DNA
<213> Chlamydia pneumoniae

<400> 3

ataagaatgc ggccgccacc atgtctttct taaggcgtca ta

42

<210> 4
<211> 37
<212> DNA
<213> Chlamydia pneumoniae

<400> 4

gcgccggtac cgaatataaa aagtttcttt attgggg

37

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00778

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C12N15/62 C12N15/85 C07K14/295 C07K16/12
A61K31/711 A61K39/118 A61K39/40 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 27105 A (GRIFFAIS REMY ; GENSET (FR)) 3 June 1999 (1999-06-03) SEQ ID NO:349 page 5, paragraph 1 abstract -----	1-31, 33, 34

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

5 December 2000

Date of mailing of the international search report

11/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 00 00778

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

As far as an "in vivo" method is concerned, claim 28 is directed to a diagnostic method practised on the human/animal body, and the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00778

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9927105 A	03-06-1999	AU 1170299 A BR 9814878 A EP 1032674 A	15-06-1999 03-10-2000 06-09-2000